

15th world
congress
on human
reproduction

Venezia Italy,
Hilton Molino Stucky
13/16 March 2013

Scientific Symposium

15th World Congress
on Human Reproduction **2013**

Venice, Italy

Sponsored by Theramex – Teva Pharmaceuticals

Natural estrogen pills: *do they change attitudes?*

March 14th 2013 13:15 to 15:15

Lunch Symposium

Co-chairs: Andrea Genazzani and Chiara Benedetto, Italy

Program

○ Introduction

Co-chair
Andrea Genazzani

Co-chair
Chiara Benedetto

○ Which prescriptions to which women ?

Andrea Genazzani, Italy

○ A specific users profile ?

Paloma Lobo, Spain

○ Women's attitudes and doctors' expectations.

Joaquin Calaf Alsina, Spain



TABLE OF CONTENTS

THE INTERNATIONAL ACADEMY OF HUMAN REPRODUCTION

THE ACADEMY	5
THE BOARD	6
THE FELLOWS.....	7
THE CONGRESSES	11

THE 15TH WORLD CONGRESS ON HUMAN REPRODUCTION

WELCOME LETTER.....	13
GENERAL INFORMATION	14
SECRETARIATS.....	14
NETWORKING ACTIVITIES	15
SCIENTIFIC INFORMATION.....	16
SATELLITE SYMPOSIUM	16
MAP OF THE CONGRESS AREA	18
EXHIBITORS AND SPONSORS	19

SCIENTIFIC PROGRAMME

CME CREDITS	28
WEDNESDAY 13 MARCH	29
OPENING LECTURE	29
THURSDAY 14 MARCH	31
PLENARY LECTURES OF THE DAY	32
FRIDAY 15 MARCH.....	41
PLENARY LECTURES OF THE DAY	42
SATURDAY 16 MARCH.....	51
PLENARY LECTURES OF THE DAY	52
POSTERS	61



European Society of Gynecology  Société Européenne de Gynécologie

10 Congress of the European Society of Gynecology Congrès de la Société Européenne de Gynécologie

Bruxelles 18/21 Sept 2013



Deadline for early registration
Apr 02 2013



More than 5,000 gynecologists
in the last two editions

Chairman of the Congress
Jean-Michel Foidart

Scientific Secretariat
Marc Robbiano
marc.robbiano@chu.ulg.ac.be

Organizing secretariat
Biomedical Technologies srl
www.btcongress.com

www.SEG2013.com



Joseph G. Schenker
President of the
International Academy
of Human Reproduction

Dear Friends,

As President of the International Academy of Human Reproduction it is my pleasure to welcome you to the 15th World Congress on Human Reproduction.

Since the establishment of the Academy by our late friend the distinguished Brazilian gynecologist, A. Campus De Paz, we had 14 World Congresses and I think the list is quite impressive.

The World Congress became the most significant venue for the scientific exchange in human reproduction, with high quality of papers and debates. A truly international gathering of scientists and clinicians who are working in their respective countries to advance our collaborative agenda and making progress in the science of Human Reproduction.

In 2011 we have taken another step in developing a sustained Academy under the name of “International Academy of Human Reproduction -IAHR-” a no-profit association governed by Swiss Civil Code.

The main objectives of IAHR are:

- To extend the knowledge in all aspects of human reproduction, fertility and infertility, and family planning, as well as population affairs.
- To encourage exchange of clinical experience and promote scientific thought and investigation.
- To consider ethical and social implications of the current practice of human reproduction and reproductive biology.

The Fellows of the Academy are selected among those applicants from the fields of clinical medicine, medical and biological sciences, and other fields related to reproductive health and medicine. Fellows are elected on basis of their singular and significant contributions to the field and they must be acknowledged as world leaders in their discipline.

Our Congress promotes excellence in reproduction and aims to bridge gaps between the expansion of information and its implementation in clinical practice.

The advances in technology and scientific knowledge have created new ethical dilemmas, which may influence societies around the world. These will be broadly discussed.

I welcome you in the romantic city of Venice to share with you in the next four days the most pressing issues facing clinicians and scientist in the field of reproduction today.

Board and Members

President

Joseph G. Schenker (IL)

Executive

Mettler Liselotte (DE)

Genazzani Andrea R. (IT)

Sciarra John J. (US)

Birkhäuser Martin (CH)

Active Fellows

Barri Pedro N. (ES)

Benagiano Giuseppe (IT)

Beier Henning M. (DE)

Ben-Rafael Zion, (IL)

Coutifaris Christos (US)

Creatsas George K., (GR)

Devoto Luigi C., (CL)

Diedrich Klaus (DE)

Di Renzo Gian Carlo (IT)

Gomel Victor (CA)

Holzgreve Wolfgang (CH)

Khomassuridze Archil (GE)

Klimek Rudolf, (PL)

Kovacs Gabor T (AU)

Kurjak Asim, (HR)

Laufer Neri (IL)

Naftolin Frederick (US)

Patrizio Pasquale (US)

Seppala Markku T (FI)

Shoham Zeev (IL)

Strauss Jerome F. III (US)

Tan Seang L. (CA)

Trounson Alan (AU)

Vartej Petrache (RO)

Honorary Fellows

Fathalla Mahmoud (ET)

Frydman Rene (FR)

A

THE ACADEMY:
BOARD AND
ACTIVE FELLOWS



Joseph G. Schenker (IL)

President of International Academy of Human Reproduction. Professor of Obstetrics and Gynecology at The Hebrew University of Jerusalem. Chairman of the Department of Obstetrics and Gynecology (Emeritus), Hadassah-University Hospital, Jerusalem. His research has involved experimental and clinical studies in the endocrinology of human reproduction, development of methods for contraception, and development of technologies in practice of assisted reproduction. He is interested in the ethical aspects of reproduction and gynecological and obstetric practice, and has chaired the Ethical Committee of IFFS and the FIGO Committee for the Study of Ethical Aspects on Human Reproduction. He has produced publications in medical journals and several books in the field of obstetrics & gynecology and reproduction.



Liselotte Mettler (DE)

Professor Dr. Med. Liselotte Mettler was born in Vienna, Austria. From 1959-1981 she did her medical studies, doctorate, medical specialist training in Obstetrics - Gynecology and Reproductive Medicine, habilitation, and professorship in Tübingen, Germany, Vienna, Austria and Kiel, Germany. Her main fields of activity are Reproductive Medicine, Gynaecological Endoscopy, Endometriosis and Gynaecological Endocrinology. Prof. Mettler is actively participating in many societies and organizations. She has written over 700 publications, 20 books and 4 textbooks. The last one of 2012 with the Kiel School of Gynecological Endoscopy entitled PRACTICAL MANUAL OF LAPAROSCOPIC AND HYSTEROSCOPIC SURGERY. She has 3 sons.

She is General Secretary of the International Academy of Human Reproduction (IAHR)



Andrea R. Genazzani (IT)

Full Professor of Obstetrics and Gynecology and nominated Director of the Department of Obstetrics and Gynecology at the University of Cagliari.

From 1^o November 1982 he was nominated Director of the Department of Obstetrics and Gynecology of the University of Modena and since 1994 up to 2012 he became Director of the Department of Obstetrics and Gynecology of the University of Pisa. In 1994 he was awarded with the Honoris Causa Laurea by the University of Wrocław in Polonia, in 2005 he was awarded with the Honoris Causa Laurea by the University "Ovidius" of Costanta in Romania, in 2007 he was awarded with the Honoris Causa Laurea by the University of Bucharest in Romania and in 2009 he was awarded with the Honoris Causa Laurea by the University of Athens in Greece. In 2011 he was entitled Professor Emeritus of the Ministry of Health and Social Development of Russian Federation.



John Sciarra (US)

John J. Sciarra, MD, PhD is Professor and Chair Emeritus of the Department of Obstetrics and Gynecology at Northwestern University Medical School. In Relation to international activities, Dr. Sciarra served as the president of the International Federation of Gynecology and Obstetrics (FIGO) and is editor emeritus of the International Journal of Gynecology and Obstetrics. At the world health organization (WHO), he served as Chair of the scientific and ethical review committee of the special program for research, education and research training in human reproduction. Dr. Sciarra is the Editor-in-Chief of the Global Library of Women's Medicine, that provides open-access educational information for physicians in over 170 countries.



Birkhäuser Martin (CH)

Martin H. Birkhaeuser gained his MD in 1969 from the Univ. of Basel (Switzerland), and specialized first in endocrinology (Univ. of Geneva), then in Gynaecol. Endocrinol. & Reprod. Medicine (ass. prof., Univ. of Basel). In 1993, he became professor and Head of the div. of Gynaecol. Endocrinol. & Reprod. Medicine at the Univ. of Berne. His special interests concern menopause (bone/lipid metabolism, quality of life, impact of HRT) and of the PCO-Syndrome. He retired on December 31th, 2008.

Martin H. Birkhaeuser is an Honorary Founding President of the Europ. Menopause & Andropause Society and has been a member of the Executive Committee of the IMS (Treasurer 2005-2008).

**Barri Pedro N. (ES)**

He graduated from the Faculty of Medicine in Barcelona in 1971. He had his training in Obstetrics and Gynecology was in Barcelona and in France and England. He received his doctorate in 1993 writing the thesis "Respuesta Anómala a la Estimulación

de la Maduración Folicular en Fecundación In Vitro" with qualification Cum Laude. In December, 2003 he is nominated A Corresponding Academician of the Reial Acadèmia of Medicine of Catalonia. He has published 102 articles and he has presented 283 lectures and 172 scientific conferences and has participated as guest professor in many national and international congresses. At present, he is the Director of the Department of Obstetrics, Gynaecology and Reproduction of the Institut Universitari Dexeus. From January, 2011 he is The Director of the Chair of Investigation in Obstetrics and Gynaecology of the Institut Universitari Dexeus of the Universitat Autònoma de Barcelona.

**Benagiano Giuseppe (IT)**

Professor Emeritus, University "la Sapienza", Rome and Senior Consultant to the President, University Campus Biomedico, Rome.

Formerly: Director, UNFPA, UNDP, WHO, World Bank Special Programme of Research in Human

Reproduction. Professor, Director of the First Institute of Obstetrics & Gynaecology and Dean the 1st Post-graduate School in Gynaecology & Obstetrics, University "la Sapienza" in Rome. Director General, the Italian National Institute of Health. Secretary general, FIGO. Visiting Professor, Ohio State University and Peking Union Medical College University, Guest Professor, Health Science Centre of Peking University. Honorary Fellow the American, Indian and Royal (British) Colleges of Obstetrics and Gynaecology; Honorary Senator, Szeged University, Hungary. Past-President, International Society for the Advancement of Contraception.

**Coutifaris Christos (US)**

Christos Coutifaris, M.D., Ph.D. is the Nancy and Richard Wolfson Professor of Obstetrics and Gynecology, Chief of the Division of Reproductive Endocrinology and Infertility and Associate Director of the Center for the Study of Epigenetics in Reproduction

at the University of Pennsylvania. He has directed research programs in reproduction under continuous NIH grant support for more than 20 years. He has served on the Division of Reproductive Endocrinology and Infertility of the American Board of Obstetrics and Gynecology, was President of the Society of Reproductive Endocrinology and Infertility and was on the Executive Board of the American College of Obstetricians and Gynecologists. He is currently on the Board of Directors of ASRM.

**Beier Henning M. (DE)**

Professor and Chairman, Institute of Anatomy and Reproductive Biology, RWTH University of Aachen, Germany (1974-2007).

Visiting Scientist, NIH (USA), NIEHS, Research Triangle Park, NC (1975-1976).

Research Consultant, Special Programme on Human Reproduction, WHO, Geneva (1972-2000).

Honorary Member of German Society of Reproductive Medicine (2007).

Professor Emeritus, Institute of Molecular and Cellular Anatomy, University Hospital Aachen (since 2008).

German National Academy of Sciences Leopoldina (ML), current responsibilities for task forces on Stem Cell Research, Legislation of Reproductive Medicine in Germany, Legislation of PGD in Germany, Collaboration of Leopoldina and Korean Academy of Sciences and Technology.

**Ben-Rafael Zion, (IL)**

- Prof. Zion Ben-Rafael, Board certified in ObGyn Israel (1983) and USA (1992).

- Previously, Professor- "Tarnesby Chair of Fertility regulation" Tel Aviv University and Chairmen, Dept of OBGYN and IVF, Rabin Medical Center, Beilinson and Hasharon Campuses.

- Currently, IVF unit Laniado Hospital.
- Publications; Total over 400 Scientific Publications; 340 original articles, 2 books written, 13 Books edited. Founder and Chairman, COGI- World Congress on Controversies in Obstetrics, Gynecology and Infertility; www.congressmed.com/cogi; Founder-Mediterranean Club Congress, that predecessor of COGI.
- Editorial Board Fertility Sterility 1993-1994; Founder and editor of a Series of debates entitled "Controversy" in the "J of IVF and Genetics" 1989

**Creatsas George K., (GR)**

George K. Creatsas is Professor of Obstetrics and Gynecology and Chairman of the 2nd Department of Obstetrics and Gynecology at the University of Athens, Greece. He served as a Dean of the University of Athens Medical School for the years

2003-2007 and as a Vice Rector of the University of Athens Greece (2006 – 2010). Professor Creatsas has published more than 376 papers with more than 3234 citations (h index 33) in international peer review Journals in the fields of corrective gynecologic surgery, menopause, pediatric and adolescent gynecology and family planning. He is the Editor of 15 proceedings and 5 books in Obstetrics and Gynecology. He is Honorary Chief Editor of the European Journal of Contraception and Reproductive Health Care, Chief Editor of the Journal of Adolescent Gynecology – Reproduction and Menopause (Greece) as well as member of the Editorial Board of the Journals: Acta Obstetrica Gynecologica Scandinavica, Gynecological Endocrinology.



Devoto Luigi C., (CL)

Dr Devoto was one of the founding director of Institute for Maternal and Child Research at the Faculty of Medicine University of Chile.

Devoto has been national and internationally recognized for his research and post graduate

research training programs in human reproduction which have been sponsored continuously by the Chilean Research Council, WHO, Rockefeller Foundation and Pharmaceutical companies. He has served as elected member of many national and international medical science organization.

Dr Devoto's research interest:

Molecular regulation of steroid biosynthesis by the human corpus luteum, Molecular mechanisms involved in human ovulation, Assisted Reproduction technology, Gynecological endoscopy.

He has published over 103 original publication in international peer review journals.



Di Renzo Gian Carlo (IT)

Prof Gian Carlo Di Renzo is currently Professor and Chair of the Department of Obstetrics and Gynecology at the University of Perugia, and Director of the Reproductive and Perinatal Medicine Center, Santa Maria della Misericordia University Hospital in Perugia,

in addition to being the Director of the Permanent International and European School of Perinatal and Reproductive Medicine in Florence, Italy. He has been principal investigator of numerous research projects for the National Research Council and for the Ministries of University and Health of Italy and of the European Union Research Projects. He has served as General Secretary of the Italian Society of Perinatal Medicine and President of the Italian Society of Ultrasound in Obstetrics and Gynecology. Prof Di Renzo has co-authored over 1100 papers and 70 books and has been invited as speaker/chairman to more than 1200 international and national congresses, meetings and courses in 90 different countries. He is a member of the Editorial Board of several international journals



Holzgreve Wolfgang (CH)

Currently he is on a sabbatical at the Institute for Advanced Study in Berlin, where he is doing research on Maternal-/Child-Health in Low Income Countries. Prof. Holzgreve's main research has been in the area of prenatal diagnosis and therapy where he has been a

strong advocate of Person-centered Medicine. Besides his involvement in the development of invasive techniques, an emphasis in research and development over the last 20 years was Non-invasive Prenatal Diagnosis from maternal blood. His research resulted in more than 500 original papers, more than 10 books, Editorial Board memberships of 15 journals and a Hirsch-index of 41. He was Editor-in-chief of the Journal Fetal Diagnosis and Therapy for many years, and currently he is the Associate Editor of the International Journal of Gynaecology and Obstetrics. He received many awards and received five honorary doctoral degrees. He was President of the German Societies of Reproductive Medicine and of Perinatal Medicine as well as President of the Swiss Society of Obstetrics and Gynaecology.



Diedrich Klaus (DE)

Ph. D. in Obstetrics and Gynecology

- Founding member of the European Society of Human Reproduction and Embryology (ESHRE) and president (1993-1995)
- Head of department of Obstetrics and Gynecology of the University Clinic of Lübeck

- Vice Dean of the University of Lübeck
- Foundation of the German-Greek Society of Obstetrics
- Medical Director of the University Hospital of Lübeck
- Medical director of the University Hospital Schleswig - Holstein, Campus Lübeck
- Doctor honoris causa of the Aristoteles University of Thessaloniki
- Doctor honoris causa of the University of Alexandroupoli
- Member of 18 national and international Editorialboards.
- Publications: 530 in national an international journals



Gornall Victor (CA)

- Former Head & Professor Department of Obstetrics & Gynecology University of British Columbia.
- President of the International Society of IVF.
- Recognized for pioneering work in both microsurgery and operative laparoscopy.

- Author of several books and numerous scientific articles published in international journals.
- Served on the editorial boards of numerous prestigious international journals
- Served in the executive and served as president of several societies.
- Received honorary membership and awards of excellence from numerous international scientific societies including ESHRE, and universities, including his own, UBC.
- Awarded, Chevalier de la Legion d'Honneur, 2003, Elected, Fellow World Academy of Art and Sciences, 2008, Doctor of Science Honoris Causa, Simon Fraser University, 2009, Awarded the prize Salat-Baroux, in reproduction, by the National Academy of Medicine of France, 2013.



Khomassuridze Archil (GE)

In 1997, at his initiation, Georgia founded a new medical discipline "Reproductology". He is the founder and the President of Georgian Association of Reproductive Health, Head of Department of Reproductology, Obstetrics and Gynaecology in Tbilisi

State University and was the initiator of introduction of Contraception, Endoscopic surgery and IVF in Georgia. He pioneered the introduction of Mifepristone in Obstetrics, Gynaecology and Reproductology in Georgia. Since 1985, under his guidance, Zhordania Institute started the study and introduction into practice of Mifepristone and this process continues today. The results of studies are published in the main foreign and Russian high impact-factor journals. Many of them were presented at different International Conferences and Symposia.

Prof. A. Khomassuridze is an author of more than 450 scientific publications, 6 monographs, 5 manuals, 3 Patents – one of them: "Mifepristone as Labor Pain-Killer".



Klimek Rudolf, (PL)

Ordinary professor of Jagiellonian University Cracow
Editor, author and co-author of over 550 publications
(papers, reviews and 53 books in gynecology, obstetrics,
oncology, endocrinology, internal medicine, sexuology and
physiology).

Main scientific achievements: Introduction for the first time in the world of hypothalamic hormones in medicine and synthetic ACTH in obstetrics, elaboration of enzymatic monitoring of pregnancy (oxytocin-oxytocinase system) and hormonal management of delivery, description of hypothalamic post-pregnancy syndrome, demonstration of different reactions of cervical vessels to the hypothalamic hormones in precancerous and cancerous stages of uterine cervix, description of neoplasms as natural, biological dissipative structures, thermodynamic theory of health and disease, introduction into gynecological practice new methods with nuclear magnetic resonance and immunotherapy of cervical intraepithelial neoplasia, description of informatonoses as a new kind of social diseases, including blameful anti-humanitarian socially tragic advertisement or action syndrome.



Kurjak Asim, (HR)

Professor of OB/GYN. Dean, School of Health Science,
Dubrovnik International University.
Publications: peer review articles – more than 400;
books (written or edited) – 104.

Coordinator of Educational Committee of WAPM; vice-president of International Academy of Perinatal Medicine, Fellow of World Academy of Art and Science; Fellow of Academy of Science and Art of Bosnia and Herzegovina; director of Ian Donald Inter-University School of Medical Ultrasound. Editor-in-chief of Donald School Journal of Ultrasound in Obstetrics and Gynecology.
Doctor Honoris causa - Universities of Banja Luka, Budapest, Barcelona, Bucharest, Athens, Montevideo, Moscow and Minsk.



Naftolin Frederick (US)

Frederick Naftolin, MD, D. Phil. was Chairman of Obstetrics and Gynecology at McGill University, 1975-8 and Yale University, 1978-2000. He has been Professor and Head of Reproductive Biology Research at New York University since 2005. Dr. Naftolin's

scientific contributions include the observation of gonadotrophin binding by the ovary, response to sheep gonadotrophin releasing hormone (GnRH), that the blood pre-ovulatory estrogen peak precedes the gonadotrophin surge, discovery of estrogen synthesis by brain tissue, discovery of the pulsatile pattern of gonadotrophin in men and women, discovery of estrogen-induced hypothalamic synaptic plasticity (EISP) and its role in GnRH/gonadotrophin feedback control, and, the existence and action of the ovarian renin-angiotensin system (OVRAS). Most recent contributions include DHEA- and sex steroid-regulated NCAM polysialylase in human blood vessel endothelium inhibits NCAM's tethering of monocytes to human vascular endothelium, and, the role of ezrin in cell transformation and cancer pathogenesis and treatment.



Kovacs Gabor T (AU)

Reproductive Gynaecologist, Subspecialist in
Reproductive Endocrinology and infertility.
Director Monash IVF.
Professor of O & G Monash University
35 years experience in IVF, Ovulation Induction, Male
subfertility, Donor Insemination and fertility surgery.

Authored/co-authored more than 160 articles, and edited/co-edited eleven textbooks (seven for Cambridge University Press). Also authored/co authored five books for the public.
Past President of Family Planning Australia and The Fertility Society of Australia, Past Chair of IVF Directors' Group Australia, and Councillor RANZCOG 1995 to 2001. Currently, Board Member Monash IVF, Isis Fertility Canberra, Carl Wood Foundation, and Northern Hospital Honorary Consultant to Family Planning Victoria.



Laufer Neri (IL)

Chairman of the Division of Obstetrics and Gynecology
at Hadassah-University Hospital
He studied at the Hebrew University, Hadassah Medical
School. He was a research fellow at the Department
of Hormone Research at the Weizmann Institute of

Science in Rehovot Israel and in 1982-1984 was an Andrew W. Mellon Fellow in Reproductive Medicine at Yale University School of Medicine. Between 1986-1988 he served as Director of the IVF Program at the Mount Sinai Medical Center in New York.
Upon his return to Israel he was Director of the IVF unit at Hadassah Medical Center in Jerusalem and from 1993-1998 Chairman of the Department Ob/Gyn at Hadassah University Hospital on Mount Scopus. In January 1999 he also became Chairman of Department Ob/Gyn at Hadassah University Hospital in Ein Kerem.
Since 1993 he is a Professor of Obstetrics and Gynecology at the Hebrew University of Jerusalem.



Patrizio Pasquale (US)

Dr. Pasquale Patrizio is a board certified specialist in Obstetrics & Gynecology, Reproductive Endocrinology and Infertility, Andrology and master in Bioethics. He is Professor and Director, Yale University Fertility Center. He is an associate Editor for Journal of Assisted

Reproduction and Genetics, section editor of the American Journal of Obstetrics and Gynecology and Reproductive Biomedicine on Line and editorial board of Fertility & Sterility. Currently is the Vice President of the International Society for Fertility Preservation (2013-2015). He has authored 3 books, 393 scientific papers (60 book chapters, 135 peer-reviewed publications and 198 abstracts) and holds 2 issued US patents (diagnostics and therapeutics). He is Honorary member of Italian Society of Fertility and Sterility, Mexico and Chile and has received prize paper awards from ASRM and ESHRE. His research interests include: Improving the efficiency of ART, reducing multiple pregnancy, fertility preservation strategies, simplify the IVF laboratory and methods to lyophilize gametes and stem cells.

**Seppälä Markku T (FI)**

Professor and Head, Dept of Ob/Gyn, Helsinki Univ Central Hospital 1979-2001. Emeritus professor & Senior Research Associate, Biomedicum Helsinki, 2001 – now. Research: Author of >400 peer-reviewed papers. Embryonic antigens in development and

cancer, endometrial proteins in implantation, functional glycomics in reproduction. Internatl activities: Population Council Board of Trustees 1985-1993. FIGO Executive Board 1985-2003; President 1997-2000; Intl Acad Hum Reprod 1990 – now, Helsinki Univ Central Hosp, Board of Governors 1992-3 and 1999-2001; Honorary member in Ob/Gyn Societies of Brazil, Chile, Finland, Hungary, Italy, Romania, Poland British Fertility Society, Chicago Society of Ob-Gyn, Society of Gynecol Invest, Doctor HC, University of Liège, Belgium

**Shoham Zeev (IL)**

Professor Zeev Shoham was born and raised in Jerusalem, Israel. He received his M.D. degree in 1981 at the Hadassah Medical Center, Jerusalem Israel.

Prof. Shoham is a specialist in Obstetrics, Gynecology and Reproductive Medicine. His current position is

the Director of the Reproductive and Endocrinology Unit at the Kaplan Medical Center in Rehovot, Israel. Prof. Shoham has published over 130 papers in the field of Reproductive Medicine, contributed chapters to numerous books, and edited two books. Prof. Shoham is the co-editor of the 4th edition of the Textbook: Assisted Reproductive Techniques: Laboratory and Clinical Perspective. Prof. Shoham originated and developed the series of congresses on Controversies in Obstetrics, Gynecology and Infertility (COGI), and later on originated the series of congress on Building Consensus out of Controversies, CRYO, Ovarian Club, Oncological Perspective of Fertility Preservation, and IVF-Worldwide Live congresses. Professor Shoham is the co-founder and is the Secretary of the Academy of Clinical Debates and Controversies in Medicine (ACDCM). Prof. Shoham is the co-founder of the most comprehensive and extensive IVF-related website to date – www.IVF-Worldwide.com

**Strauss Jerome F. III (US)**

Jerome F. Strauss, III is the Dean of the Virginia Commonwealth University School of Medicine and Executive Vice President for Medical Affairs of the VCU Health System. He sits on Board of Scientific Counselors of NICHD and the Discovery Expert

Group of the Bill & Melinda Gates Foundation. He has authored over 290 original scientific articles, and holds 12 issued U.S. patents for discoveries in diagnostics and therapeutics. His honors include the President's Achievement Award from the Society for Gynecologic Investigation (SGI), of which he is past President; the Society for the Study of Reproduction Research Award; election to the Institute of Medicine, National Academy of Sciences; the Transatlantic Medal of the British Endocrine Society, the Distinguished Graduate Award from the University of Pennsylvania School of Medicine, and the Distinguished Scientist Award from SGI. He received the Rector's Medal from the University of Chile and shared the Fondo Nestle Award for Investigations in Nutrition.

**Tan Seang L. (CA)**

Dr. Tan is Dodds Professor and Chairman of the Department of Obstetrics and Gynecology at McGill University.

He is an internationally recognized infertility expert and a pioneer in the simplification of in-vitro fertilization

(IVF). He led the team that produced the world's first air transport IVF and ICSI pregnancies and is a pioneer in Canada in the use of IVM of human oocytes for the treatment of infertility.

Dr. Tan has published 7 books and over 240 original scientific papers and review articles. He has been on the editorial board of 9 medical journals and is a member of the FIGO and Gynecology Expert Advisory Panels on Reproductive Medicine and Ultrasound and a fellow of the International Academy on Human Reproduction. He has also been awarded the Howard Eddey Gold Medal by the Royal Australasian College of Surgeons and the MRCOG Gold Medal by the Royal College of Obstetricians and Gynecologists in the United Kingdom.

**Trounson Alan (AU)**

B.Sc. (Hons), M.Sc. University NSW, Ph.D. Sydney University, Australia; Dr Honoris Causa, Vrije Universiteit Brussels; Hon LLD Monash University

Appointed the Dalgety Postdoctoral Fellow ARC Institute of Biochemistry and Reproductive Biology

(1974-6), Cambridge, UK. His scientific accomplishments include; the pioneering of human in vitro fertilisation (IVF) and associated reproductive technologies; the diagnosis of inherited genetic disease in preimplantation embryos; the discovery and production of human embryonic stem cells and their ability to be directed into neurones, prostate tissue and respiratory tissue.

In Jan. 2008-present, he was appointed President of the California Institute for Regenerative Medicine, responsible for the management of the fund for stem cell research in California (CIRM). He has overseen and extraordinary development of basic science which has led to more than 1000 publications (24% in high impact factor journals) in peer reviewed journals in the 4 years of his tenure as President.

**Vartej Petrache (RO)**

Professor and head of the Department of Ob/Gyn in the Bucharest University Hospital.

He is Author and co-author of 14 monographies and over 400 scientific articles.

He was an active participant at several Medical

Congresses in Romania and abroad.

He serves on the editorial boards of several medical journals.

He is President of the Romanian Society of Ob/Gyn, of the Romanian Society of Endocrinological Gynecology, and member of the: Romanian Academy of Medical Sciences, International Society of Gynecological Endocrinology, European Society of Investigations in Ob/Gyn, Society for the Study of Pathophysiology of Pregnancy - Organisation Gestosis, World Society of Labour and Delivery, European Society of Gynecological Oncology, Medical Balkan Union, Honorary Member of the Hungarian Society of Ob/Gyn, Member of International Academy of Human Reproduction, and Doctor Honoris Causa of the University of Medicine and Pharmacy of Kishinev (Moldavia).

HONORARY FELLOWS



Frydman Rene (FR)

Professor Frydman is part of the Faculty of Medicine at University Paris XI and is the Head of the Department of Gynecology and Obstetrics of Antoine Beclere Hospital, since 1990. Professor Frydman has held several national positions including.

Professor Frydman received the honor of Chevalier of the French Order Of Merit and is an Officer of the French Legion d'Honneur. His special areas of interest in Gynecology and Obstetrics include infertility and high-risk pregnancy. His work in infertility led the first baby born as a result of in vitro fertilization In France, in 1982. His other area of interest has been biomedical ethics. His work in this realm led to many invitations by religious authorities of the Vatican, Jerusalem and of the Reform Church to debate the moral issues created by the use of the techniques of artificial procreation. He was active in the preparation of the law on bioethics and actively worked with the Medecins du Monde and Medecins sans Frontieres.



Fathalla Mahmoud (ET)

Mahmoud F. Fathalla, from Egypt, is professor of Obstetrics and Gynecology, and was Dean of the Medical School in Assiut University for 8 years. He joined the World Health Organization in 1986, and was Director of the UNDP/UNFPA/WHO/World Bank

Special Program of Research, Development and Research Training in Human Reproduction till 1992. He received the United Nations Population Award in 2009. He was President of the International Federation of Gynecology and Obstetrics from 1994 to 1997, and Chairman of the WHO Global Advisory Committee on Health Research from 2000-2005, and Chairman of the IPPF Medical Advisory Panel from 1986- 1992.



CONGRESSES



1st Congress 1974 Rio de Janeiro, Brazil

2nd Congress 1979 Tel Aviv, Israel

3rd Congress 1981 Berlin, Germany

4th Congress 1983 Bombay, India

5th Congress 1985 Athens, Greece

6th Congress 1987 Tokyo, Japan

7th Congress 1990 Helsinki, Finland

8th Congress 1993 Bali, Indonesia

9th Congress 1996 Philadelphia, USA

10th Congress 1999 Salvador, Brazil

11th Congress 2002 Montreal, Canada

12th Congress 2005 Venice, Italy

13th Congress 2009 Venice, Italy

14th Congress 2011 Melbourne, Australia

15th Congress 2013 Venice, Italy

Save the date

The next congress will be in Berlin, Germany at the Intercontinental Hotel from 19 to 21 March 2015.



In 2015 we wait
for you in Berlin.



16TH WORLD
CONGRESS
on human
reproduction



18/21 MARCH 2015
BERLIN, GERMANY
INTERCONTINENTAL HOTEL

www.humanrep2015.com



Andrea Riccardo Genazzani
Chairman of the 15TH
World Congress of Human
Reproduction

Dear Friends and colleagues,

My warmest welcome to the 15TH World Congress of Human Reproduction.

The congress programme underlines the role that our Academy has in the world of Reproductive Medicine.

The congress covers the most important areas from basic science to clinical application to support the concept that a practitioner in Reproductive Medicine have to up-date its knowledge, to make possible the achievement of an healthy pregnancy at the proper time.

The Congress widely explores the areas of Contraception, Menopause, Reproductive Surgery, Hormone Therapies on different organs and systems, as well as how to early detect and protect from gynecological cancers and to save reproductive possibilities.

Assisted Reproductive Technologies will be discussed starting from the latest data on gametes, fertilization and implantation, till the new therapies for follicular maturation, early pregnancy protection, and management of high risk pregnancy.

With such a great and interesting programme, I wish you all to enjoy the Congress and the “magic” Venice.



Congress secretariat desk

The Congress Secretariat will be available for our delegates at the following hours:

Wednesday March 13 TH	08.30 - 20.00
Thursday March 14 TH	08.00 - 18.30
Friday March 15 TH	08.00 - 18.30
Saturday March 16 TH	08.00 - 18.00

On site Registration Fees (VAT Included)

Delegate	€ 800,00
Delegate (from Developing Countries WHO list)	€ 700,00
Residents, nurses and technicians (status to be certified)	€ 550,00

Registration Fee for the Delegate includes:

- Opening Ceremony
- Closing Ceremony
- Access to all sessions and exhibition area
- Congress kit
- Abstract Book/CD
- CME credits

Personal Data Protection Law no. 196/2003

Personal data collected directly and/or through third parties by controller and processor Biomedical Technologies. Main Office in Cagliari Via Cugia 1, are processed in printed, computing and telematic form for fulfilling contractual and lawful obligations as well as for the effective handling of business relations. The email addresses provided may be used by Biomedical Technologies to send advertising materials on events similar to those subject of the present business relations. The non-submittal of data, where no compulsory, will be evaluated from case to case by the controller and the resulting decisions to be made will take into account the importance of the required data in respect of the business relations, management. Data may be disclosed in Italy and/or abroad, strictly in accordance with the

above-mentioned purposes, and consequently processed, only in relation to the mentioned purpose, by other persons: professionals and consultants as well as by persons allowed to access to your personal data according to National or Community regulations. If necessary, for the above-mentioned reasons, your data may be disclosed to third parties. For the same reasons, our partners and/or employees may process your data in their capacity of executors or processors. The persons concerned may exercise all the rights set forth in art. 7 of L. n. 196/2003 (including the rights of data access, corrections, updating, objects to data processing and cancellation). The processor "pro tempore" is the legal representative of the company.

Organizing Secretariat

Biomedical Technologies srl
www.biomedicaltechnologies.com
Main Office and Accounting Department
Via P. Cugia 1 – 09129 Cagliari – Italy
T. +39 070340293 – F. +39 070307727
humanrep2013@btcongress.com

Marketing Office

Via Metauro 19-00198 Roma – Italy
T. +39 068546198 F. +39 0685389063
marketing@btcongress.com

Congress Venue

Hilton Molino Stucky
Giudecca 810, 30133,
Venice, Italy
www.molinostuckyhilton.it

Scientific Secretariat

Artini P.G.
Simoncini T.

www.HUMANREP2013.com
www.HUMANREPAcademy.org

G

Official Language

Official language of the Congress is English, except for the two Italian Courses.

Insurance

The Congress Organizers cannot accept liability for personal injuries, loss or damage to property belonging to Congress delegates (or their accompanying persons), either during or as a result of the Congress or during their stay in Venice. It is therefore recommended that delegates arrange their own personal health, accident and travel insurance.

Badges

All registrants including registered accompanying persons will receive a badge. Your personal badge allows you access to all Sessions and Exhibition Area. Please remember to always wear your badge. If you have lost your badge, a new one can be purchased at the Congress Secretariat.

Certificate of attendance

You will find your certificate of attendance together with your badge. Please check it and in case you need any change come from Friday March 15TH to the “New Registrations Desk”.

Customer Satisfaction

You will be given the Customer Satisfaction Form with your congress bag. Please do not ignore it. It is a Compulsory Service as Biomedical Technologies is Quality Certified and moreover you help us to improve our services. The handback of the Customer Satisfaction Form is compulsory to receive the UEMS certificate and ECM.

Coffee

Get free coffee or hot drinks at any time during the congress from the automatic beverage dispensers located near the Exhibition Area.

Lunch Symposia

Lunch boxes must be eaten inside the Congress Hall.

March 14TH 13.30 - 15.15 Hall Venice 1+2

Natural estrogen pills: do they change attitudes?
(Sponsored by TEVA)

March 15TH 13.30 - 15.15 Venice 1+2

Focus on progesterone: the pregnancy hormone
(Sponsored by IBSA)

March 16TH 13.15 - 15.00 Venice 1

Ethical aspects in reproduction

March 16TH 13.15 - 15.00 Venice 1

Sexuality

N

Poster Session and cocktail

Wednesday March 13th

starting from 18.00
in the Poster Area

Cocktail and visit to Scuola Grande di San Rocco

Friday March 15th

Please come to the Social Desk before 12.00 on Friday to collect your ticket and entrance time. Tickets will be distributed on “first come first take” basis. No entrance can be allowed without entrance ticket.

Meeting point: Scuola Grande di San Rocco San Polo, 3052 Venezia. From the Molino Stucky You can take line n. 2 of the public service transportation (see www.actv.it) until San Tomà and reach Scuola Grande di San Rocco on foot (walking distance: 10 minutes).

Computer projection

Computer projection is provided in all conference rooms via direct link with the preview room. No projection through own computers is allowed. Kindly bring your presentation on a multimedia support (CD-Rom, Pen Drive) as a PowerPoint file. Please remember that the first slide of your presentation has to show your photo along with the name underneath. No other software is accepted. No Slide Projector is provided.

Preview rooms

Speakers are kindly requested to hand over their Powerpoint presentation at the preview room near the Internet Area. Presentations must be brought at least one hour before their session. Speakers presenting in the early morning sessions should ensure that they have handed over their slides during the previous afternoon.

Oral presentations

Oral Presentations will last about 8 minutes each plus 2 minutes discussion. The presenters are kindly requested to respect the time allotted for each presentation.

Poster session

The Poster Session will take place on March 13TH from 18.00 to 20.00. Poster Authors should stand by their Posters for presentation and discussion. Posters must be set up on Wednesday 13TH from 12.00 to 17.00 and dismantled Friday 15TH between 16.00 and 18.30. The maximum size of the posters must be 90cm x 90cm. The organizers cannot be held responsible for posters not removed on time.

The posters award

Three posters will be awarded each with a free registration to the 16TH World Congress on Human Reproduction (Berlin, March 19 – 21 2015) including a free accommodation for one person (overnight stay in a 3 stars hotel, double room). The awards will be given during the Closing Ceremony on Saturday March 16TH.

SATELLITE SYMPOSIUM

New Horizons in IVF Genetic Diagnosis

17-19 MARCH 2013 ALICANTE, SPAIN
WWW.GENETIC-DIAGNOSIS-ALICANTE.COM

- ▶ This workshop intends to be interdisciplinary and inter-active, allowing not only deep inside into the newest results and approaches of pre-conceptional, pre-implantational and prenatal screening, but also demo shows and hands-on training regarding the most advanced ART biopsy techniques around PGD and PGS on Polar Bodies and trophoctoderm.

The course will focus on the state of the art of molecular screening of embryos in the context of IVF, on realistic scenarios regarding the further development of this field, and on the ethical and social implications.



Opening Symposium

Wednesday 13th March 2013

14.00 - 16.00 - Hall Venice 1+Venice 2

New challenges in gynecology

Chairmen: Fauser B., Genazzani A.R.

How to improve compliance in contraception:

Compliance issues raised by the different treatment regimens with oral hormonal contraceptives
Serfaty D.

Impact of different hormonal contraceptives on sexual function and well-being
Nappi R.E.

Medical therapy for uterine myomas:

The SPRM Ulipristal acetate: biological effects
Bouchard P.

Ulipristal acetate: the clinical impact
Donnez J.

Faculty

Professor Philippe Bouchard
Professor of Medicine and Head of Endocrinology, Hôpital St Antoine
Assistance Publique, Hôpitaux de Paris (APHP), France

Professor Jacques Donnez
Prof emeritus University of Louvain
Belgium

Professor Bart C.J.M. Fauser
Chair, Division Woman & Baby (including Departments Reproduction & Gynecology, Obstetrics, Neonatology, and PsychoNeuroimmunology laboratories)
University Medical Center Utrecht, The Netherlands


Professor Andrea R Genazzani (Co-chair)
President of the International Society of Gynecological Endocrinology
Professor of Obstetrics and Gynecology, University of Pisa, Italy

Professor Rossella Elena Nappi
Department of Obstetrics and Gynecology
IRCCS San Matteo Foundation, Pavia, Italy

Doctor David Serfaty
President of the French Society of Gynecology and the Francophone Society of Contraception, Honorary President of the European Society of Contraception, France

1st floor

Ground floor



Ground Floor

- Hall Venice 1
- Hall Venice 2
- Hall Venice 3
- Speakers Preview Room
- Internet Area
- Poster Area

Exhibition Area

- ① Abbott
- ② Ibsa
- ③ MSD
- ④ Besins
- ⑤ Pfizer
- ⑥ Bayer
- ⑦ Lo.Li Pharma
- ⑧ Gedeon Richter
- ⑨ Origio
- ⑩ Sweetchild Group
- ⑪ Rottapharm
- ⑫ Teva
- ⑭ DuoFertility
- ⑮ Wisepress
- ⑯ Cic

First Floor

- Hall Goldoni
- Hall Casanova

E

EXHIBITORS AND SPONSORS



Abbott Products Operations AG

EPD Established Pharmaceuticals Division
 Hegenheimerweg 127
 4123 Allschwil / Switzerland
 Tel: +41 61 487 0200

Abbott's Established Pharmaceuticals Division (EPD), headquartered in Basel, Switzerland, is focused on helping make the world a healthier place by bringing the benefits of trusted pharmaceutical brands to much broader patient populations – in the developed world and, particularly, in emerging markets. EPD brings value to its patients and customers through deep localization and a growing portfolio of high-quality established pharmaceutical products. Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

Alfa Wassermann Spa

I - 65020 Alanno (PE) - Via E. Fermi, 1
 info@alfawassermann.it - www.alfawassermann.it
 Founded in 1948, Alfa Wassermann S.p.A. holds a prominent position in the Italian pharmaceutical market. Its activities include research, production and commercialisation of prescription drugs and self-medication products. The head office and research laboratories are located in the company's historical headquarters in Bologna, while the modern production plant located in Alanno (Pescara) also carries out contract manufacturing. The International Division is headquartered in Milan. The company, which employs over 670 people in Italy and over 1,200 worldwide, ended 2008 with a turnover of 273 million Euro and a 10.6% growth. The fact that over 60% of the company's turnover is generated by its own products constitutes one of the strengths of Alfa Wassermann S.p.A. These products are the result of internal research and include several leading drugs in their relative market segments.

Bayer Pharma AG

Muellerstr. 178 13342 Berlin Germany

Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. We market our products in more than 100 countries, and in 2010 generated sales of almost €11 billion.

More than 38,000 members of staff currently work for Bayer HealthCare Pharmaceuticals worldwide – more than 6,200 in research and development alone. We aim to improve people's quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products. In this context, Bayer HealthCare Pharmaceuticals uses experience it has gained from over a century in the business. We concentrate on four business areas in which we make essential contributions to medical progress.

General Medicine

Specialty Medicine

Women's Healthcare

Diagnostic Imaging

Specialist in women's health

With our products, we promote the health of women at different stages of life, and help them to shape their lives according to their own wishes. With this philosophy, we are consolidating our leading market position in the field of Women's Healthcare, and this applies to all three areas in which we concentrate our activities: hormonal contraception, menopause management and gynecological therapy.

Besins Healthcare SA

Besins Healthcare Operations Coordination Center Co., Ltd.
 283/92 Homeplace Building, 18th Floor, Soi Sukhumvit 55
 (Thonglor),
 Sukhumvit Road, Klongton Nua, Wattana, Bangkok 10110,
 Thailand
 www.besins-healthcare.com

Besins Healthcare is a pharmaceutical company specialized in the development and worldwide diffusion of innovative drugs and food supplements for the well-being of men and women. The company has established a strong reputation in gynaecology over the last 30 years and is a renowned actor

in hormonal therapies. Our products are distributed in more than 90 countries via our own subsidiaries or a network of business partners. We plan to pursue our expansion in new territories to bring to the company significant growth over the coming years. Visit our site to understand why Innovating for well-being is our claim (www.besins-healthcare.com)

Cic edizioni internazionali

Corso Trieste 42, 00198 Roma, Italy
t. +39068412673 f. +39068412688
info@gruppocic.it - www.gruppocic.it

Cic edizioni internazionali is a publishing house with more than 40 years of experience and over 10 years of publishing periodicals and volumes specializing in various medical fields. Cic edizioni internazionali is particularly present in the obstetric-gynecology sector.

Edizioni Minerva Medica

Corso Bramante 83 10126 Torino
Tel +39 011 678282 Fax +39 011 674502
minervamedica@minervamedica.it www.minervamedica.it

Edizioni Minerva Medica publishes specialist journals and books distributed worldwide since 1909. Our mission is to gather, process, and deliver content that's essential and informative. We accomplish this goal through print, CD-ROM, and internet publications. The journal *Minerva Ginecologica* is a publication on obstetrics and gynecology and is essential reading for 5,000 clinicians in the field of gynecology. The journal is indexed by Index Medicus/ PubMed.

Ferring Pharmaceuticals

Via Senigallia, 18/2 20161 Milano Italy
Tel. +39 02 64000143 - Fax. +39 02 64000120
www.ferring.it - laura.realini@fering.com

Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.

Ferring has its own production facilities in several European countries, in South America, Israel and China and is

currently building new facilities in the US and India. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.

Ferring's marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 50 countries and employ more than 4500 people throughout the world, while treatments are available in more than 90 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.

Ferring's R&D projects complement Ferring's product portfolio and will add a new generation of products to some of the company's most successful specialty brands. R&D facilities are located in Denmark, USA, Israel, India and China.

Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.

Gedeon Richter Itaita srl

Viale Cassala 16 20143 Milano
Tel. 039 02 4953 9953

Founded in Hungary in 1901, Gedeon Richter is a Pan-European innovation-driven specialty pharmaceutical company with business in 100 different countries around the world.

Gedeon Richter produces more than 200 conventional medications in over 400 different pharmaceutical formulations. The aim of the company is to be a reliable partner for gynecologists and women offering a wide range of high quality therapeutic formulations and a complete line of gynecological products. The pipeline includes Esmya, which had the approval of EMA on February 2012, for the pre-surgical treatment of uterine fibroids.

Besides carrying out original research, the company is also engaged in the development of generic drugs and chemical processes as well as biotechnology.

The ability of Gedeon Richter, recognized worldwide, in steroid chemistry, its skill in developing new active substances, the efficient production and its productive sites able to meet strict

quality assurance requirements, are a winning combination that guarantees a solid base for future development.

Gedeon Richter is present in Italy since April 2011 and it is marketing the oral contraceptive portfolio Belara, Daylette, Liladros, Midiana and Sibilla, one food supplement for cystitis, Myrtilmax and one for pregnant and breast feeding women, IncinDha.

The company aims at expanding its gynecological portfolio in the hormonal contraception as well as in the treatment of gynecological benign pathologies.

HRA Pharma

HRA Pharma is an emerging European pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide.

A pioneer in emergency contraception since the launch of its first product in 1999, NorLevo®, HRA Pharma has engineered a robust portfolio and pipeline in the fields of reproductive health and endocrinology which it maximizes through in-licensing and out-licensing agreements.

The company targets and tackles therapeutic gaps and uses innovative marketing solutions and socially-conscious programs to promote healthy management of drug and diseases worldwide.

Headquartered in Paris, France with local teams based at subsidiaries in Germany (Bochum), the United Kingdom (London), Italy (Roma), Spain (Madrid) and the United States (New York City), HRA Pharma is privately-owned.

The company has forged a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 50 countries across the globe.

HRA Pharma makes the difference by combining its health mission with a socially conscious approach to ensuring that its products are accessible everywhere.

IBSA Institut Biochimique SA

Company Address: IBSA Institut Biochimique SA
Via del Piano, P.O. Box 266,
6915 Pambio-Noranco, Lugano, Switzerland
Tel. +41 58 360 10 00 - Fax. +41 58 360 16 47
www.ibsa-international.com - info@ibsa.ch

IBSA is an international pharmaceutical company headquartered in Lugano, Switzerland, delivering different therapeutic solutions for follicular stimulation and luteal support.

IBSA developed an entirely new purification process to obtain a full range of highly purified, human gonadotrophins: hFSH, hMG and hCG.

This unique patented process was conceived to ensure at the same time both high purity and the respect of the structure—correlate activities of the gonadotrophins (natural glycosylation).

IBSA's whole in-house manufacturing ensures the same global quality system in company owned plants, from the first steps of raw materials to the final lyophilized products. Other company's franchises include osteoarthritis, pain-management, dermatology and thyroid diseases.

LJ Pharma

LJ Pharma is an independent pharmaceutical group of private ownership, with a long experience in the national market of nutraceutical, medical device, cosmetic and pharmaceutical products. Our mission is to achieve a greater involvement at the present to make a better future. To accomplish this, we offer products of a high scientific standard to fit patients' needs and contribute to the knowledge of the medical community about new improvements in medicine and pharmacology, while keeping in touch with health professionals and patients. LJ Pharma distributes women's health products. Our aim is to support woman during all life's stages offering innovative and effective solutions for minor daily disorders and for high social impact diseases. For this purpose, LJ Pharma has developed a new concept in male and female infertility treatment, offering innovative nutraceutical products, in order to make the difference between cure and care.

Our "non-pharmaceutical solutions for Infertility" represent

an effective alternative to the traditional pharmacological approach and improve the quality of life of the patients. Our target is exclusively represented by specialists in the treatment of infertility problems.

LJ Pharma has also developed a Multivitamin line especially designed to give energy and vitality needed to face pregnancy and nursing. The first choice to improve pregnancy history.

LJ Pharma products

Nutraceutical innovation for female's infertility treatment:

Chirofol, Chirofert 100

Nutraceutical innovation for male infertility treatment:

Chiroman Multivitamin Line for Pregnancy: Multifolico DHA, Multifolico oro, Folico 3 mesi

Innovative solution for inflammatory diseases: Peroxen, Alfarepagin, Lactofin, Micoschiuma.

LO.LI. Pharma

LO.LI.Pharma International is the International branch of LO.LI.Pharma, a growing Pharmaceutical Company, based in Rome, dedicated to research, development and distribution of Medical Devices Functional Dietary Supplement..

The Company is mainly focused on fertility but its portfolio of Products is expanding in several different areas, such as Neurology, Dermatology, Endocrinology and others.

The company's key success factor is the continuous effort in developing products able to meet community's expectations and requirements.

Nowadays LO.LI.Pharma's products are marketed in nearly 30 countries, not just in Europe, but even in South and North America, Asia and Northern Africa, and many more on the their way to join them.

The Company's success is the result of a great teamwork where different people with different skills cooperate to assure the highest standards of quality, safety and efficacy from the raw material to the finished product.

Menarini OTC

Via Sette Santi 3 50131 Firenze
www.menarini.it.

Menarini is the first Italian pharmaceutical group in the world and ranks 15th in Europe and 34th world-wide.

Menarini's territorial presence covers more than 100 countries in Europe, Asia, Africa and Australia and, in the year 2010, its consolidated worldwide turnover exceeded 3 million Euro with a headcount of more than 13,000.

The Menarini Group currently markets products for the most important therapeutic fields: cardiovascular, gastroenterology, oncology, metabolism, antibiotics and respiratory drugs, products for the treatment of diabetes, anti-inflammatories and analgesics and operates through several 'divisions' such as Research, Prescription Drugs, OTC, Diagnostics, Manufacturing and Field Force.

Menarini's Headquarters are located in Florence.

For further information please consult our website.

Merck Sharp & Dohme

1 Merck Drive - Whitehouse Station, New Jersey, USA
Tel. +1 908 423 1000 - www.msd.com

Today's MSD is a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. After the merger with Schering Plough and Organon in 2010, MSD became global healthcare leader for Women's Health. For more information, visit www.msd.com

Origio

Via L. Giordano 7/B/C/D 50132 Firenze Italia
Tel. +39 055 571476 www.origio.com

Origio is a leader in delivering innovative Assisted Reproductive Technology solutions that enhance the work of ART professionals to the benefit of families.

Pfizer Inc

500 Arcola Road, Collegeville Pa 19426, USA
www.pfizer.com

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Rottapharm|Madaus

Founded in 1961 by Prof. Luigi Rovati as an independent research laboratory, Rottapharm|Madaus is today a multinational pharmaceutical group operating in around 85 different countries worldwide with a workforce of more than 2,000. The group mission: to improve people's quality of life, thanks to intense, constant research.

Rottapharm|Madaus can boast a full portfolio of original drugs and molecules, discovered and patented by their in-house R&D division in the areas of rheumatology, gynaecology, cardiology and gastrointestinal sciences.

The work of Rottapharm|Madaus has extended to cover the field of prevention and general personal wellbeing. Today the Company is proud to boast an undisputed leadership position in personal care products sold in the pharmacy, in hygiene care (Saugella, Babygella) and in dermocosmetics (Biomineal, Biothymus).

The role played by Rottapharm|Madaus in the nutraceutical product sector is worthy of separate mention. With the

launch of Estromineral in 2001, the group entered the nutraceutical market. The product – a natural supplement based on soy isoflavones for treating the symptoms of menopause – today leads the field in the pharmacy. Rottapharm's cardiology and rheumatology know-how later resulted in the launch of new products: Armolipid for natural cardiovascular protection, and Fortilase, a bromelain-based supplement with excellent anti-inflammatory and anti-oedema properties. To these we add the historic sun supplements of the Carovit line, to prepare the skin for photoexposure, and the Biomineal line for systemic hair care.

The personal care production plant – originally a pharmaceutical production plant, and later converted to dermo-cosmetics and nutraceuticals – is situated in Confienza, at the edge of Pavia, Italy.

Thanks to the technology used and resources involved, it is able to guarantee extremely high efficiency and quality levels, making the plant avant-garde in the development and production of dermo-cosmetics and intimate hygiene products, as well as for medical devices and food supplements in tablet form.

The demineralised water plant and distribution circuit are worthy of separate note, which can guarantee the supply of highly purified water as required to develop the products, ensuring constant pharmaceutical standard quality levels. The laboratories have been equipped for Quality Control, chemical and microbiological analyses in addition to Research and Development. Production quality is guaranteed by certifications ISO 9001 and ISO 13485, and by Good Manufacturing Practices (ISO 22716).

Rottapharm|Madaus is committed to working in a sustainable manner in each of the major areas of impact of its activities: -responsible research: because the primary responsibility of R|M is people's health. The commitment to discovering new therapies and to constantly improving the quality of their products form the basis for the major investments made in R&D.

The additional services provided, with a view to supporting pharmacies in after-sales too, include a pharmacist dedicated customer care service, allowing him/her to request information in support of his/her profession and on how to use Rottapharm|Madaus products correctly. Additionally,

alongside the pharmaco-vigilance services (for notifying side effects involved in ethical or prescription drugs), there is also a cosmetics-vigilance service (for information and notifications on personal care products and medical devices) and a nutra-vigilance service dedicated to nutraceuticals.

Sweetchild Companies' Group

Russia, Moscow, Tsvetnoy Boulevard, 24 – Building 1

Tel. +7(495)608-22-73

pankina@sweetgroup.ru www.surrogacymed.com

Sweetchild Companies' Group has been operating in the field of surrogacy and egg donation for over 10 years. In that time we had hundreds of clients enter into contract with us. Now these clients are raising their own children, who were given birth by our surrogate mothers, and we have grown from a small legal firm into a major multi-purpose holding company that operates in the area of assisted reproductive technologies in Russia.

Many of those, who went through our surrogacy programs and became happy parents, return to us for their "next child" and recommend us to their relatives.

We are the best, and this is recognized by other players on the market. With us you will become happy parents!

THERAMEX/TEVA Women's Health Europe

6 Avenue Albert II. BP 59 98007 Monaco

Valerie Adancourt or Caroline Mullot Reynier

Tel. + 377.92.05.08.08

vadancourt@theramex.mc; creynier@theramex.mc

www.theramex.mc

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 850 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached

\$18.3 billion in net revenues in 2011

About Teva Women's Health in Europe

Teva's Women's Health business in Europe was established following the acquisition of Théramex in January 2010. Teva/Theramex offers a large portfolio of products in the areas of gynaecology, osteoporosis, peri-menopause, menopause and contraceptives, and includes trusted brand names such as Orocal®, Colpotrophine®, Lutenyl®, Monazol®, Estreva®, Antadys®, Leeloo® Ge, Nacrez® and ZOELY® the first monophasic pill containing natural estrogen.

Wisepress Medical Bookshop

25 High Path Merton Abbey London SW19 2JL UK

Phone: +44 20 8715 1812 Fax: +44 20 8715 1722

bookshop@wisepress.com www.wisepress.com

Wisepress.com, Europe's leading conference bookseller, has a complete range of relevant books and journals which can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. We also have a comprehensive medical and scientific online bookshop with great offers.

Opening Symposium

Wednesday 13th March 2013

14.00 - 16.00 - Hall Venice 1+Venice 2

New challenges in gynecology

Chairmen: Fauser B., Genazzani A.R.

How to improve compliance in contraception:

Compliance issues raised by the different treatment regimens with oral hormonal contraceptives
Serfaty D.

Impact of different hormonal contraceptives on sexual function and well-being
Nappi R.E.

Medical therapy for uterine myomas:

The SPRM Ulipristal acetate: biological effects
Bouchard P.

Ulipristal acetate: the clinical impact
Donnez J.

Faculty

Professor Philippe Bouchard

Professor of Medicine and Head of Endocrinology, Hôpital St Antoine Assistance Publique, Hôpitaux de Paris (APHP), France

Professor Jacques Donnez

Prof emeritus University of Louvain
Belgium

Professor Bart C.J.M. Fauser

Chair, Division Woman & Baby (including Departments Reproduction & Gynecology, Obstetrics, Neonatology, and PsychoNeuroimmunology laboratories) University Medical Center Utrecht, The Netherlands

Professor Andrea R Genazzani (Co-chair)

President of the International Society of Gynecological Endocrinology
Professor of Obstetrics and Gynecology, University of Pisa, Italy

Professor Rossella Elena Nappi

Department of Obstetrics and Gynecology
IRCCS San Matteo Foundation, Pavia, Italy

Doctor David Serfaty

President of the French Society of Gynecology and the Francophone Society of Contraception, Honorary President of the European Society of Contraception, France

15th world
congress
on human
reproduction

Venezia Italy,
Hilton Molino Stucky
13/16 March 2013

Scientific Programme

CME CREDITS	28
WEDNESDAY 13 MARCH	29
OPENING LECTURE	29
THURSDAY 14 MARCH	31
PLENARY LECTURES OF THE DAY	32
FRIDAY 15 MARCH	41
PLENARY LECTURES OF THE DAY	42
SATURDAY 16 MARCH	51
PLENARY LECTURES OF THE DAY	52
POSTERS	61



15 credits



UEMS Credits (Europe)

The European Accreditation Council for CME is an official body of the European Association of Medical Specialists (UEMS) being established by the UEMS Management Council meeting in October 1999.

The UEMS (European Union of Medical Specialists) has assigned to the 15th World Congress on Human Reproduction n.15 Continuous Medical Education European (CME) credits. These credits are valid for all European Community Countries and are recognized by the American Medical Association toward the Physician's Recognition Award (AMA) for Canada and North American Countries.

UEMS to AMA conversion

Physicians may apply to convert European credit into AMA credit by completing and returning the EACCME application, along with the appropriate application processing fee and documentation of the meeting Physicians have attended. Please check the UEMS website (www.uems.net) to ensure the activity attended is listed and marked as "Approved" before submitting the application. The credits are one-to-one

ECM Credits (italian delegates)

The following course is certified with ECM credits:

Friday March 15th 15.45-18.00 Hall Venice 3
Ginecologia ambulatoriale: dalle sinergie specialistiche alla scelta di cura (1 Credit)

In order to obtain credits from the Continuous Medical Education Programme the following steps are mandatory:

- Attend the full ECM sessions
- Fill in the ECM Questionnaire that you will receive at the beginning of the course
- Fill in the Customer Satisfaction Form
- Kindly remember that the Questionnaire together with the Customer Satisfaction Form will have to be handed back to the ECM Desk before the end of the Congress.
- The Questionnaire has validity only when accompanied by the completed Customer Satisfaction Form.
- The ECM certificate will be sent to the participants, via post or email, after evaluation of the answers.

	HALL VENICE 1+2	HALL GOLDONI
09.00-13.00		Pre-congress Course Applying a new evidence-based medical treatment approach to clinical practice (Sponsored by Bayer)
14.00	Opening Session (Sponsored by Gedeon Richter) New challenges in gynecology	
14.00-15.00	How to improve compliance in contraception	
15.00-16.00	Medical therapy for uterine myomas	
16.30-17.00	Opening Ceremony	
17.00-17.15	Special Celebration	
17.15-18.00	Opening Lecture Ovarian Aging: Can science turn back the clock?	
18.00-20.00	Poster Session in the poster area	

OL

OPENING LECTURE

17:15/18:00 Hall Venice 1

Ovarian Aging: Can science turn back the clock?

Tilly Jonathan L. (US)

For decades it was believed that mammalian females generate their entire quota of oocytes during embryogenesis, leading to endowment of a fixed pool of oocyte-containing follicles at birth. However, the recent discovery of mitotically active oogonial (oocyte-producing) stem cells (OSCs) in adult mouse and human ovaries provides evidence that the postnatal mammalian oocyte pool is actively replenished (Nature 2004 428:145; Nature Cell Biol 2009 11:631; Differentiation 2010 79:159; Nature Med 2012 18:413; Reprod Sci 2013 20:7). Such a paradigm shift would draw strong parallels to the maintenance of adult spermatogenesis by spermatogonial stem cells in the testes, as well as to the continuous production of oocytes during adulthood in less evolved species such as flies and fish (Semin Reprod Med 2013 31:24). One of the most significant advances in this emerging field was provided by a new study (Nature Med 2012 18:413) reporting the isolation and functional characterization of OSCs from ovaries of reproductive age women. In as-yet unpublished work, we have found that these cells persist in mouse and human ovaries with advancing age, even when oocyte loss is complete. In mice, these cells resume production of new oocytes once transferred to a young adult ovarian microenvironment (Aging 2009 1:971). Based on these and other observations, we are exploring the possibility that ovarian failure with age is preventable if not reversible by targeting these oocyte-producing stem cells, or the niches in which they reside, *in vivo*. We have also developed novel strategies using OSCs to combat the decline in egg quality with age, as

a means to improve outcomes in human assisted reproduction (Fertil Steril 2012 98:3). Lastly, based on prior studies showing that sustaining ovarian function into advanced ages in mice (Nature Genet 1999 21:200) leads to remarkable health benefits, including a maintenance of muscle mass, bone density, vision, hearing and cognitive function (Proc Natl Acad Sci USA 2007 104:5229), such efforts to extend ovarian lifespan may one day prove immensely beneficial to the general health and well-being of women.



Tilly Jonathan L. (US)

Dr. Tilly obtained his Ph.D. in 1990, completed postdoctoral fellowships at University of California-San Diego and Stanford University, and joined the faculty of Johns Hopkins in 1993. He moved to Massachusetts General Hospital (MGH) in 1995 as Associate Professor

of Obstetrics, Gynecology & Reproductive Biology at Harvard Medical School (HMS) to develop and direct the MGH Vincent Center for Reproductive Biology. He was promoted to Professor at HMS in 2009. Dr. Tilly's current studies focus on his discovery of germline stem cells in ovaries of adult mice and women that are capable of generating new oocytes (Nature 2004; Nature Medicine 2012). In 2011, he co-founded a biotech company focused on use of his patented technologies for improving or restoring female fertility (OvaScience, Cambridge, MA; www.ovascience.com).

HALL GOLDONI

09:00/13:00 PRE-CONGRESS COURSE

(Sponsored by BAYER)

Applying a new evidence-based medical treatment approach to clinical practice

CHAIRMANSHIP: CHERN BERNARD (SG)

Chern Barnard (SG) Asian Insights into Endometriosis
 Ebert Andreas (DE) Challenges in management of endometriosis
 Petta Carlos (BR) Medical Management before and after surgery
 Seitz Chris (DE) Evidence-based Treatment with Visanne
 Leyland Nicholas (CA) Clinical Experience with Visanne

HALL VENICE 1

14:00 OPENING SESSION - NEW CHALLENGES IN GYNECOLOGY

(Sponsored by Gedeon Richter)

CHAIRMANSHIP: GENAZZANI ANDREA RICCARDO (IT), FAUSER BART (NL)

14.00-15.00 How to improve compliance in contraception

Serfaty David (FR) Compliance issues raised by the different treatment regimen with oral hormonal contraceptives
 Nappi Rossella Elena (IT) Impact of different hormonal contraceptives on sexual function and well-being

15.00-16.00 Medical therapy for uterine myomas

Bouchard Philippe (FR) The SPRM Ulipristal acetate: biological effects
 Donnez Jaques (BE) Ulipristal acetate: the clinical impact

16:30/17:00 OPENING CEREMONY

CHAIRMANSHIP: GENAZZANI ANDREA RICCARDO (IT)

Schenker Joseph (IL) Ciciarella Raffaele (IT) Sciarra John J. (US) Mettler Liselotte (DE)

17:00/17:15 SPECIAL CELEBRATION

CHAIRMANSHIP: BUEHLER KLAUS (DE)

17:15/18:00 OPENING LECTURE

Tilly Jonathan L. (US) Ovarian Aging: Can science turn back the clock?

HALL VENICE 3

18:00/20:00 POSTER SESSION

Posters list - P.61

	HALL VENICE 1	HALL VENICE 2	HALL VENICE 3	HALL GOLDONI	HALL CASANOVA
08.30-09.30	Scientific Society Symp. IMS -updated ims recommendations on HRT- have we come full circle?	Meet the experts Adenomyosis	Meet the experts New horizons in IVF genetic diagnosis	Scientific Society Symp. Polish Society of Gynecological Endocrinology	Oral Presentation Abortion
09.45-11.15	Sponsored symposium The pill: benefits, risks, counselling (Sponsored by Bayer)	Plenary session Prenatal diagnosis	Plenary session Adolescence	Sponsored symposium Selection of the top embryo, a quest of the holy grail? (Sponsored by Uteron)	Oral Presentation Ovulation induction
11.15-11.45	Exhibit visit				
11.45-13.15	Sponsored symposium A new evidence-based treatment approach in endometriosis (Sponsored by Bayer)	Plenary session High risk pregnancy	Plenary session Ovulation: different patient, different approach	Plenary session Fertility Preservation In Cancer Women Undergoing Chemotherapy	Oral Presentation Gynecological Endocrinology and Contraception
13.30-15.15	Lunch Symposium Natural estrogen pills: do they change attitudes? (Sponsored by Teva)				
15.15-15.45	Exhibit visit				
15.45-16.15	Plenary Lecture Ulipristal for emergency contraception: it's time to change (Sponsored by HRA)	Plenary Lecture Novel role of ER Signaling in fertilization and early embryo development	Italian Teaching Course La versatilità dell'estroprogestinico come strumento di salute nelle diverse età della donna (Sponsored by Teva)	Plenary Lecture Vit D and Sex Hormones in Women and Men	
16.30-18.00	Plenary session Breast	Plenary session Abnormal uterine bleeding		Sponsored symposium Hyperandrogenism in women today – the role of CPA (sponsored by Bayer)	Oral Presentation Ethics And Psychology In Reproductive Medicine

15.45-16.15 Hall Venice 1

Ulipristal for Emergency contraception: it's time to change.

(sponsored by HRA Pharma)

Nappi Rossella E. (IT)

Although many valid methods of contraception are available, however, even today, there are many unwanted pregnancies, which unfortunately in most cases hesitate in voluntary abortion.

This reason led to the development of emergency contraception (EC) methods, as contraceptive backup that can come in handy in these cases of failure or improper use of a contraceptive method or its non-use in order to avoid incurring a voluntary interruption of pregnancy.

From the first experiences with high doses of estrogen, via the Yuzpe method and once-only levonorgestrel as EC, the use of selective progesterone receptor modulators (ulipristal acetate) for this indication has arrived in Europe few years ago. The advantage of this new preparation resides in its capacity to ensure the block of ovulation even very close to the LH peak, or rather in the phases of the cycle where the old levonorgestrel are no longer able to act.

To act efficiently, the EC pills should be administered as soon as possible after unprotected sex, and ulipristal, if administered within the first 24 hours, has been shown to be able to decrease by 2/3 the risk of unwanted pregnancy compared with levonorgestrel. Therefore, EC should be part of contraceptive counseling.

15.45-16.15 Hall Venice 2

Novel Role of ER Signaling in Fertilization and Early Embryo Development

Korach Kenneth S. (US)

Estrogens stimulate the female reproductive tract via estrogen receptor alpha (ER α), to grow and regulate gene responses. Reproductive tissue is comprised of several cell types, including myometrial, stromal, glandular and luminal epithelial cells, all of which contain ER α protein and epithelial specific Wnt7a-Cre ER α knock out (cKO) mice showed loss of epithelial ER α from the uterus causes female infertility, in part, due to an implantation defect. Infertility may also be due to loss of ER α activity in the oviduct since epithelial ER α conditional knockout (cKO) mice showed loss of their embryos between days 1 and 2 of pregnancy. Although similar numbers of oocytes were ovulated, only ~50% of oocytes collected from the cKO oviducts were fertilized when compared to control littermates, and no 2-cell embryos were ever recovered on pregnancy day 2. The fertilization rate of the cKO oocytes was restored control littermate levels only when the oocytes were collected directly from the ovaries prior to ovulation and then fertilized in vitro. Furthermore, when wild type zygotes were transferred into oviducts of pseudopregnant cKO mice, the majority of the embryos were under-developed when flushed from the oviduct at 3.5 dpc, and no embryos were found in the uterus. In contrast, all transferred embryos collected from pseudopregnant control littermates were morulas or blastocysts, and all embryos reached the uterus. These findings suggest that ablation of ER α in the oviductal epithelium results in alterations in the oviductal microenvironment that completely disrupts fertilization, preimplantation embryo development and embryo transport. Microarray analysis of cKO and control oviducts collected at 0.5 and 1.5 dpc demonstrated significant alterations in expression of genes involved in interleukin 17 signaling and prostaglandin D2 synthesis. These findings were confirmed at the protein level by analysis of IL17 and prostaglandin D synthase. It can be concluded that epithelial ER α is required to establish the appropriate oviduct environment for successful mouse preimplantation embryo development. Our findings demonstrate a highly novel and unexpected regulatory phenomenon of epithelial ER α in the female reproductive tract that has the potential to provide a better understanding of idiopathic infertility in women.

15.45-16.15 Hall Goldoni

Vitamin D and Sex Hormones

Milewicz Andrzej (PL)

In tissues of many organs also in ovaries, testis and adrenal the vitamin D receptor (VDR) and its metabolizing enzymes activity were found. It is also date which demonstrated important role of vit. D in female reproduction including IVF and PCOS. Our study consisted of 214 young women (26,4+/-5,8 yrs), shows that women (n=41) with vit. D deficiency (< 20,0ng/ml) had significantly higher BMI, waist circumference, Free Androgens Index and lower serum SHBG levels in comparison to PCOS women with normal vit. D levels (n=66) and controls. In other study (PolSenior) of aging women and men we show seasonal changes of vit. D levels and sex hormones serum levels. Women with low serum vit. D levels show lower serum DHEAS levels. In men we observed lower serum SHBG, DHEAS levels and FAI. Vit. D serum levels were not correlated with serum sex hormones in aging women and men. High quality randomized study are required to determine the effect of vit. D supplementation on fertility in women and men.



Rossella E. Nappi

Associate Professor of Obstetrics and Gynecology, Research Center for Reproductive Medicine and Director of the Gynecological Endocrinology & Menopause Unit, IRCCS San Matteo Foundation, University of Pavia (Italy) MD, PhD Gynecologist, Endocrinologist,

Sexologist

Dr Nappi's major interest is focused on psychoneuroendocrinology of female reproductive life and women's sexuality. She has published more than 150 scientific articles in peer-reviewed journals and international books. She is a well known speaker on women's health from adolescence to menopause and has been featured in many international meetings.

She is past president of the International Society for the Study of Women Sexual Health (ISSWSH) (200-7-2008) and member of the advisory board of the International Menopause Society (IMS).



Korach Kenneth S.

Kenneth S. Korach is the Director of the Environmental Disease and Medicine Program, Chief of the Laboratory of Reproductive and Developmental Toxicology at the National Institute of Environmental Health Sciences. He received his Ph.D. in Endocrinology from the

Medical College of Georgia where he characterized biochemical properties of estrogen receptors in the pituitary and hypothalamus and post doctoral training at Harvard Medical School. At NIEHS his research group investigates estrogen hormone action in numerous tissues by the generation of the ERKO mouse models with an application towards understanding the basic mechanisms of estrogens influence on physiological processes. Ken was an Editor and past Editor-in-Chief for Endocrinology.



Milewicz Andrzej

Specialization: ENDOCRINOLOGY – clinical endocrinology INTERNAL DISEASE
From 1989 Head of Department of Endocrinology and Diabetology, Wrocław Medical University
From 2003 till now President of Polish Endocrine Society

CURRENT RESEARCH

1. Endocrinology of ageing
2. Endocrinology of obesity
3. Insulin resistance and hyperandrogenism
4. Metabolic disorders (cardiovascular risk ,osteoporosis) in menopause and andropause
5. PCOS



150 Years
Science For A Better Life

As a pioneer in Women's Healthcare, Bayer HealthCare Pharmaceuticals focuses on three areas: contraception, menopause management, and the development of gynecological therapies.

Bayer HealthCare Pharmaceuticals is the global leader in Women's Healthcare, in particular in the area of oral contraception and intrauterine systems. For more than 50 years, the "pill" has enabled women to plan their families.

To meet the needs of individual women, Bayer HealthCare Pharmaceuticals offers a wide range of different contraceptives including a low-dosage contraceptive which is the first product in a new class of oral contraceptives whose estrogen component has the same action as estradiol, an estrogen that is produced by the female body.

The Women's Healthcare range also includes products to relieve the symptoms associated with menopause. In the gynecological therapy segment, the company is developing new therapeutic options for conditions with a high level of unmet medical needs such as uterine fibroids (myomas) and endometriosis, a condition in which endometrial cells grow outside of the uterus. Bayer HealthCare Pharmaceuticals recently launched a product for the treatment of endometriosis.

www.bayerpharma.com



150 Years
Science For A Better Life

Symposia

Symposia

Bayer HealthCare Pharmaceuticals cordially invites
you to our symposia:

**Pre-congress Teaching Course on Endometriosis
Applying a New Evidence-based Medical Treatment Approach to
Clinical Practice**

Chaired by Bernard Chern (Singapore)

March 13, 2013 · 09:00–13:00 · Hall Goldoni

The Pill: Benefits, Risks, Counselling

Chaired by Philip Smits (Germany)

March 14, 2013 · 09:45–11:15 · Hall Venice 1

A New Evidence-based Treatment Approach in Endometriosis

Chaired by Charles Chapron (France) and Andreas D. Ebert (Germany)

March 14, 2013 · 11:45–13:15 · Hall Venice 1

Hyperandrogenism in Women Today – The Role of CPA

Chaired by Ruan Xianyang (China) and Rui Ferriani (Brazil)

March 14, 2013 · 16:30–18:00 · Hall Goldoni

**Modern Menopause Management – Why is Progestin Choice
so Important?**

Chaired by: Nick Panay (UK) and Yu Qi (China)

March 15, 2013 · 11:45–13:15 · Hall Goldoni

HALL VENICE 1

08:30/09:30 SCIENTIFIC SOCIETY SYMPOSIUM

organized by International Menopause Society

UPDATED IMS RECOMMENDATIONS ON HRT- HAVE WE COME FULL CIRCLE?

CHAIRMANSHIP: BIRKHAUSER MARTIN (CH), NAPPI ROSSELLA (IT)

Panay Nickolas (GB) IMS guidelines - so what is new?

Gompel Anne (FR) IMS guidelines - addressing the risks of breast cancer, what do we know now?

Gambacciani Marco (IT) IMS guidelines - understanding the future in bone

09:45/11:15 SPONSORED SYMPOSIUM

(Sponsored by Bayer)

THE PILL: BENEFITS, RISKS, COUNSELLING

CHAIRMANSHIP: SITRUK-WARE REGINE (US), SMITS PHILIP (FR)

Smits Philip (FR) The Pill: Introduction, Benefits

Szarewski Anne (US) The Pill: Risks

Shulman Lee (GB) The Pill: Choices

11:45/13:15 SPONSORED SYMPOSIUM

(Sponsored by Bayer)

A NEW EVIDENCE-BASED TREATMENT APPROACH IN ENDOMETRIOSIS

CHAIRMANSHIP: EBERT ANDREAS D. (DE), CHAPRON CHARLES (FR)

Simoncini Tommaso (IT) Pathophysiology of Endometriosis & Rationale for Progestin Therapy

Leyland Nicholas (CA) Dienogest in the Evidence-based Medical Management of Endometriosis

Petta Carlos (BR) Clinical Experience with Dienogest

13:30/15:15 LUNCH SYMPOSIUM

(Sponsored by TEVA)

NATURAL ESTROGEN PILLS: DO THEY CHANGE ATTITUDES?

CHAIRMANSHIP: GENAZZANI ANDREA RICCARDO (IT), BENEDETTO CHIARA (IT)

Genazzani Andrea R. (IT) Which prescriptions to which women?

Calaf Alsina Joaquin (ES) Women's attitudes and doctors' expectations

Lobo Paloma (ES) A specific users profile?

15:45/16:15 PLENARY LECTURE

(Sponsored by HRA)

CHAIRMANSHIP: ANGIONI STEFANO (IT), BRUNI VINCENZINA (IT), DEI METELLA (IT)

Nappi Rossella (IT) Ulipristal for Emergency contraception: it's time to change.

16:30/18:00 PLENARY SESSION

BREAST

CHAIRMANSHIP: BRINGAT MARK (MT), GADDUCCI ANGIOLO (IT)

Biglia Nicoletta (IT) Breast cancer in young women

Gompel Anne (FR) Normal breast of BRCA1 mutation carriers

Simoncini Tommaso (IT) Hormonal control of breast cancer metastasis

Lachowsky Michèle (FR) Breast cancer and sexuality

HALL VENICE 2

08:30/09:30 MEET THE EXPERTS

ADENOMYOSIS

CHAIRMANSHIP: ANGIONI STEFANO (IT), EBERT ANDREAS D. (DE)

Benagiano Giuseppe (IT) Adenomyosis and infertility

Hamou Jacques (FR) Hysteroscopy Treatment Of Adenomyosis In Infertility

09:45/11:15 PLENARY SESSION

PRENATAL DIAGNOSIS

CHAIRMANSHIP: LYALL FIONA (UK), EXACOUSTOS CATERINA (IT)

Gianaroli Luca (IT) PGD: clinical impact and new trends

Kurjak Asim (Hr) The assessment of structural and functional early human development by 3D and 4D sonography

Luchi Carlo (IT) Change to the future: new perspectives in fetal cardiac surgery

11:45/13:15 PLENARY SESSION

HIGH RISK PREGNANCY

CHAIRMANSHIP: FACCHINETTI FABIO (IT), VISSER GERARD (NL)

Lyall Fiona (UK) Mechanisms underlying placental dysfunction in pre-eclampsia

Ferrazzi Enrico (IT) Metabolomics and the biophysical indices of the fetus with chronic and acute hypoxia

Reiter Russel (US) Placental Melatonin: Function as an Antioxidant in the Fetus and Mother

Visser Gerard (NL) Women are designed to deliver vaginally: is that really true?

15:45/16:15 PLENARY LECTURE

CHAIRMANSHIP: GOLDSTEIN STEVEN R. (US)

Korach Kenneth (US) Novel Role of ER Signaling in Fertilization and Early Embryo Development

16:30/18:00 PLENARY SESSION

ABNORMAL UTERINE BLEEDING

CHAIRMANSHIP: CELA VITO (IT), ALMEIDA-SANTOS ANA TERESA (PT)

Hamou Jacques (FR) Contribution of diagnostic and operative hysteroscopy prior to IVF

Goldstein Steven (US) Endometrial evaluation in perimenopausal women

Gambacciani Marco (IT) From hormone therapy to minimally invasive surgery

Kiesel Ludwig (DE) Chemotherapy-induced amenorrhoea (CIA)

HALL VENICE 3

08:30/09:30 MEET THE EXPERTS

NEW HORIZONS IN IVF GENETIC DIAGNOSIS

CHAIRMANSHIP: BEN RAFAEL ZION (IL)

Schmutzler Andreas (DE) New Horizons In IVF Genetic Diagnosis

Horcajada Jose (ES) New Horizons In IVF Genetic Diagnosis

09:45/11:15 PLENARY SESSION

ADOLESCENCE

CHAIRMANSHIP: GENAZZANI ALESSANDRO (IT), STRAUSS III JEROME (US)

Dei Metella (IT) - Bruni Vincenzina (IT) The diagnosis of genital malformations in adolescents

Sultan Charles (FR) The XY adolescent female: more frequent than we imagine

Creatsas George (GR) Contraception for adolescents and sexually transmitted diseases

Tarlatzis Basil (GR) PCOS

11:45/13:15 PLENARY SESSION

OVULATION: DIFFERENT PATIENT, DIFFERENT APPROACH

CHAIRMANSHIP: SCHENKER JOSEPH (IL), KOVACS GABOR (AU)

Fauser Bart (NL) Female health implications of PCOS

Devoto Luigi (CL) Luteal phase dysfunction associated with ovarian stimulation

Ferraretti Anna (IT) Poor Ovarian Responders in ART: definition, prevalence and prognosis

Diedrich Klaus (DE) IVF: 10 years of successes and failures

15:45/18:00 ITALIAN TEACHING COURSE

(Sponsored by TEVA)

LA VERSATILITÀ DELL'ESTROPROGESTINICO COME STRUMENTO DI SALUTE NELLE DIVERSE ETÀ DELLA DONNA

CHAIRMANSHIP: NAPPI ROSSELLA (IT), GENAZZANI ALESSANDRO (IT)

Lello Stefano (IT) L'Equilibrio Estro-progestinico

Dei Metella (IT) I Criteri di scelta - Adolescenti

Cagnacci Angelo (IT) I Criteri di Scelta - Donne in età fertile

Gmabacciani Marco (IT) I Criteri di Scelta - Premenopausa

HALL GOLDONI

08:30/09:30 SCIENTIFIC SOCIETY SYMPOSIUM

POLISH SOCIETY OF GYNECOLOGICAL ENDOCRINOLOGY

CHAIRMANSHIP: MECZEKALSKI BLAZEJ (PL)

Baranowski Wlodzimierz (PL) Fertility preservation in patients after oncological treatment

Katulski Krzysztof (PL) Pregnancy complications in PCOS patients

Meczekalski Blazej (PL) What do we actually know about ovarian ageing?

Milewicz Andrzej (PL) Serum sex hormones levels in Ageing Polish Population and Cardiovascular Risk Factor-PolSenior Study

Breborowicz Grzegorz (PL) Value of progestosterone supplementation in early pregnancy

09:45/11:15 SPONSORED SYMPOSIUM

(sponsored by UTERON)

SELECTION OF THE TOP EMBRYO, A QUEST OF THE HOLY GRAIL?

CHAIRMANSHIP: GENAZZANI ANDREA RICCARDO (IT)

Fauser Bart (NL) Good quality embryos as the key determining factor for a successful IVF Program

Foidart Jean-Michel (BE) Human embryo transfer strategy based on combined assessment of follicular fluid G-CSF level

11:45/13:15 PLENARY SESSION

FERTILITY PRESERVATION IN CANCER WOMEN UNDERGOING CHEMOTHERAPY

CHAIRMANSHIP: BIGLIA NICOLETTA (IT), GOMPEL ANNE (FR)

Gadducci Angiolo (IT) Potential effect of chemotherapy on future fertility

Trèves Rachel (FR) Psychological and ethical impacts of fertility preservation in cancer women

Cobo Ana (ES) Oocyte cryopreservation for cancer patients

Santos Teresa (PT) Fertility preservation in breast cancer

15:45/16:15 PLENARY LECTURE

CHAIRMANSHIP: GAMBACCIANI MARCO (IT)

Milewicz Andrzej (PL) Vitamin D and Sex Hormones

16:30/18:00 SPONSORED SYMPOSIUM

(sponsored by Bayer)

HYPERANDROGENISM IN WOMEN TODAY THE ROLE OF CPA

CHAIRMANSHIP: RUAN XIANGYAN (CN), FERRIANI RUI (BR)

Panay Nicholas (GB) Pathophysiology and clinical signs of hyperandrogenism in women - a fresh look at an old problem

Mueck Alfred (DE) The current role of antiandrogens in the clinical management of hyperandrogenism in women

Petta Carlos (BR) Spotlight on EE/CPA - hyperandrogenism therapy in practice

HALL CASANOVA

08:30/09:30 ORAL PRESENTATION

ABORTION

CHAIRMANSHIP: BRINCAT MARK (MT), CAGNACCI ANGELO (IT)

Schiavon Raffaella (MX) Increasing abortion-related hospitalization rates among adolescents in Mexico, by age group and by state of residence

Ventolini Gary (US) Lupus Anticoagulant Positive: What is the outcome of the subsequent pregnancy? A Cohort Study.

Bashiri Asher (IL) The effect of interpregnancy interval on outcomes of pregnancy after recurrent pregnancy loss.

Barros Venina (BR) Obstetrics outcomes associated with an increased level of Lipoprotein-A (LP-A) in thrombophilic patients.

Barros Venina (BR) High level of cholesterol and triglycerides are associated with bad pregnancy outcomes and thrombosis in pregnancy

09:45/11:15 ORAL PRESENTATION

OVULATION INDUCTION**CHAIRMANSHIP: COBO ANA (ES), FERRARETTI ANNA PIA (IT)**

Veliscu Andreea (RO) Progesterone levels at the beginning of IVF stimulation and estrogen supplementation during luteal phase –increased pregnancy rate

Aizyatulova Elmira (UA) Using of GnRH antagonist depending on the serum progesterone level in controlled ovulation stimulation in infertile women with high risk of ovarian hyperstimulation syndrome

Barkalina Natalia (RU) Elevated progesterone on the day the hCG administration in a three-day GnRH antagonist pre-treatment protocol for controlled ovarian stimulation in IVF/ICSI cycles: incidence and impact

Vityazeva Irina (RU) Correlation of controlled ovarian stimulation and thyroid status in women undergoing invitro fertilization and embryo transfer

Alghabshi Rahma (SA) Are Blood Groups Associated with the Prediction of Ovarian Reserve in Patients undergoing IVF treatment?

Reznikov Alexander (UA) Non-steroidal antiandrogen facilitates gonadotropin induction of ovulation in polycystic ovaries: from animal research to clinical trial

11:45/13:15 ORAL PRESENTATION

GYNECOLOGICAL ENDOCRINOLOGY AND CONTRACEPTION**CHAIRMANSHIP: BENAGIANO GIUSEPPE (IT), FRUZZETTI FRANCA (IT)**

O'flynn Mary (IE) Can oral medication be used to treat nuisance bleeding after LNG-IUS insertion?

Foegh Marie (US) Participant and Investigator Assessments Show Excellent Patch Adhesion and Low Incidence of Skin Irritation and Itching in a Phase 3 Study of TwirlaTM, a New Contraceptive Patch

Howard Brandon (US) Multinational, Multicenter, Randomized, Open-label Study to Evaluate the Impact of a 91-day Extended Cycle Oral Contraceptive (OC) Regimen, Compared to Two 28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy Women

Magalhaes Jarbas (BR) The IUS-LNG for treatment of HMB due to idiopathic menorrhagia, adenomyosis and fibroids (Brazilian Experience)

Croxatto Horacio (CL) Oral administration of meloxicam on a continuous regimen does not effectively suppress ovulation in women

Santagni Susanna (IT) Progestins of oral contraceptives do not modulate LH response to GnRH stimulation test

Czyzyk Adam (PL) Arterial stiffness and central hemodynamics in patients with functional hypothalamic amenorrhea.

Zabolotnov Vitaliy (UA) Menstrual function in obese adolescent girls

Garcia Otero Laura (ES) Role of X chromosome in the development of human osteoporosis in patients with TS.

16:30/18:00 ORAL PRESENTATION

ETHICS AND PSYCHOLOGY IN REPRODUCTIVE MEDICINE**CHAIRMANSHIP: GIANAROLI LUCA (IT), TREVES RACHEL (FR)**

Schwartz Erika Schwartz (US) Learning how to talk to patients.

Behruzi Roxana (CA) The impact of the perinatal policy 2008 of Quebec on the inter-professional and inter-organizational relation between birthing homes and hospitals in Quebec: Collaboration or conflict?

Lockwood Gillian (GB) Societal and Demographic implications of 'Social' egg freezing

Wånggren Kjell (SE) Attitudes towards embryo donation among infertile couples having frozen embryos

Mancini Antonio (IT) Oocyte donation and pregnancy risk: a case report

Simoglou Vassiliki (FR) Not pregnant following egg donation IVF

Panagiotoopoulou Nikoletta (GB) Ethical issues in posthumous reproduction: a systematic literature review.

Beauquier-Maccotta Berengere (FR) Embryo representations in couples attending a embryo gift.

	HALL VENICE 1	HALL VENICE 2	HALL VENICE 3	HALL GOLDONI	HALL CASANOVA
08.30-09.30	Scientific Society Symp. Gonadotropins and ovulation: from basic science to clinics (organized by International Society of Gynecological Endocrinology - ISGE)	Meet the experts Pelvic ultrasounds: the atypical issues	Scientific Society Symp. Salute sessuale e salute riproduttiva (organized by Federazione Italiana di Sessuologia Scientifica - FISS)	Scientific Society Symp. organized by: Mediterranean Society For Reproductive Medicine (MSRM)	Oral Presentation Early pregnancy
09.45-11.15	Plenary session Progestins and antiprogestins	Sponsored symposium Myo-Inositol: a breakthrough in the treatment of polycystic ovary syndrome and ovulation induction (Sponsored by L.O.L.I Pharma)	Plenary session Surgery and fertility	Sponsored symposium A new era in contraception: non oral administration (Sponsored by MSD)	Oral Presentation Menopause
11.15-11.45	Exhibit visit				
11.45-13.15	Sponsored symposium Micronized progesterone is safe and unique in HRT (Sponsored by Besins)	Plenary session The unmet needs in maternal-fetal medicine	Plenary session Implantation	Sponsored symposium Modern menopause management – why is progestin choice so important? (Sponsored by Bayer)	Oral Presentation Endocrine disorders in the two genders
13.30-15.15	Lunch Symposium Focus on progesterone: the pregnancy hormone (Sponsored by Ibsa)				
15.15-15.45	Exhibit visit				
15.45-16.15	Plenary Lecture Women's health, past, present and future	Plenary Lecture Complications of assisted reproductive technologies	Italian Teaching Course Ginecologia ambulatoriale: dalle sinergie specialistiche alla scelta di cura (Sponsored by Pfizer)	Plenary Lecture Female elite athletes and hidden XY DSD	
16.30-18.00	Plenary session Endometriosis up to date from diagnosis to therapies	Plenary session Menopause: new challenges, new solutions		Plenary session The hypogonadal male	Oral Presentation New techniques in medically assisted procreation

15.45-16.15 Hall Venice 1

Complications of Assisted Reproductive Technology
Schenker Joseph G. (IL)

ART is basically a safe procedure. However, as with any method, a few patients will experience side effects and complications. A recent study showed that overall mortality in IVF pregnancies was higher than the maternal mortality rate in the general population (42 mothers' deaths per 100,000 IVF pregnancies compared to 6 deaths per 100,000 pregnancies overall). The most common complications associated with IVF are the failure of treatment, medical complications as a consequence of ovarian stimulation, (OHSS). Ovarian stimulation effects, both the coagulation and fibrinolytic systems. Ovarian hyperstimulation syndrome can be associated with both arterial and venous thrombotic complications. As with any invasive procedure, there is a risk of bleeding or infection. IVF-pregnancies are associated with more obstetric complications: pre-eclampsia, placental abruption and postpartum haemorrhage. Pregnancies at advanced maternal age after oocyte donation have an increased risk of obstetrical complication.

It was suggested that children conceived artificially are more at risk of low birth weight, premature birth, stillbirth or death shortly after birth. Recently, more sophisticated analysis found that these extra risks for single pregnancy are the fault of existing fertility problems in the parents and not the techniques used during assisted fertilization methods. A greater chance of low birth weight is associated with multiple pregnancies that with present policy of number of embryos transferred can be prevented. In addition, to medical complications that arise from IVF treatments, there are serious errors or near misses including loss of embryos, sperm or egg. In most cases, either the wrong sperm was injected into an oocyte or the embryos were destroyed accidentally, or even implanted into another woman. ART contributes to the change of family unit structure.

15.45-16.15 Hall Venice 2

Why should all postmenopausal women be treated the same? - Identification of the right HRT/SERM, at the right dose at the right time for the right patients!
Christiansen Claus (CH)

Despite abundant evidence of a protective effect of exogenous female sex hormones in relation to osteoporosis, considerable controversy exists regarding as the causal role of ERT and HRT in terms of cardiovascular disease and breast cancer risk. Moreover, the female predominance of polyarticular osteoarthritis (OA) and in particular the marked increase of OA in women after menopause point to a likely involvement of female sex hormones in the maintenance of joint homeostasis.

Timely initiated ERT/SERM treatment may effectively prevent, and be protective of, different pathologies; however the cost-benefit for the individual patients needs to be carefully assessed and ascertained. Recently we have developed the serological tool for measurement for circulating levels of oestrogen receptors, ERalpha and ERbeta, which enable accurate quantification of the respective concentrations of ligand and receptors. This may better enable the identification of the right dose of the right ERT/SERM for the right postmenopausal women for personalized health care.

In conclusion, the pleiotropic effect of estrogens on several different tissues may better match complicated representation of postmenopausal health, rather than a single treatment targeted at one specific organ. This is the first step towards personalized medicine for postmenopausal women, allowing for evidence based therapy selection of estrogens and thereby possible opening a new era of estrogen research after the women health initiate (WHI) findings.

15.45-16.15 Hall Goldoni

Elite young female athletes and hidden XY disorders of sex development

Sultan Charles (FR)

Context: Although a rare occurrence, previously undiagnosed disorders of sex development (DSD) with hyperandrogenism are sometimes detected during the international sports competitions and their hormonal screening. Identifying the cause of XY,DSD raises medical and ethical concerns, especially with regard to issues of the eligibility to compete.

Objective: The aim of this study was to determine whether the detection of high plasma testosterone (T) in young elite female athletes during antidoping programs would reveal an unsuspected XY DSD.

Setting: The study was performed in the Nice and Montpellier University Hospitals, which collaborate as reference centers for DSD in elite athletes on behalf of the International Association of Athletics Federations.

Patients: Four cases of elite young athletes with female phenotypes but high plasma T detected during hormonal screening were investigated for undiagnosed XY DSD.

Main Outcome Measures: Evaluation of clinical, biological, radiological (MRI and DEXA) and genetic characteristics.

Results: The four athletes presented as tall, slim, muscular women with a male bone morphotype, no breast development, clitoromegaly, partial or complete labial fusion, and inguinal/intralabial testes. All reported primary amenorrhea. The hormonal analysis evidenced plasma T within the male range, the karyotype was 46,XY, and molecular analysis of 5 α reductase type 2 (srd5A2) gene identified a homozygotic mutation in two cases, a heterozygotic compound in one case, and a deletion in one case.

Conclusion: 5 α reductase deficiency should be investigated in all elite young female athletes with high plasma T detected during antidoping programs and primary amenorrhea in order to identify hidden XY DSD.



Schenker Joseph G.

President of International Academy of Human Reproduction. Professor of Obstetrics and Gynecology at The Hebrew University of Jerusalem. Chairman of the Department of Obstetrics and Gynecology (Emeritus), Hadassah-University Hospital, Jerusalem.

His research has involved experimental and clinical studies in the endocrinology of human reproduction, development of methods for contraception, and development of technologies in practice of assisted reproduction. He is interested in the ethical aspects of reproduction and gynecological and obstetric practice, and has chaired the Ethical Committee of IFFS and the FIGO Committee for the Study of Ethical Aspects on Human Reproduction He has produced publications in medical journals and several books in the field of obstetrics & gynecology and reproduction.



Christiansen Claus

Professor Claus Christiansen is Charimann of Nordic Bioscience A/S, and Executive Director and Chairmann of CCBR/Synarc. He received his medical education at the University of Copenhagen, Denmark in 1971, and held the post of Head of the Department of Clinical

Pathology and Clinical Chemistry, Glostrup Hospital, University of Copenhagen for 14 years. Hereafter he founded Center for Clinical and Basic Research (CCBR) where he was the Executive Director from October 1992 – December 1996 and from November 1999 – February 2007. Over the past 30 years, Professor Christiansen has published extensively in the field of osteoporosis with over 950 articles and book chapters, particularly in the area of calcium metabolism in postmenopausal women. He has been Chairman of several international symposia on osteoporosis, and has been an invited speaker on calcium metabolism at almost all international meetings in the field. In addition, he is a member of the Editorial Boards of the journals Bone and Osteoporosis International.



Sultan Charles

Charles received his MD degree from the University of Montpellier School of Medicine in France and then did his pediatric training at Nimes University Hospital. He was also a Chief Resident of Pediatrics at Montpellier University Hospital.

He received a PhD in Endocrinology from the University of Montpellier School of Sciences and was a Postdoctoral Fellow at The Johns Hopkins Hospital for 18 months, in the Department of Pediatric Endocrinology under Professor Migeon.

Charles had published more than 300 papers in peer-reviewed journals and contributed more than 100 chapters and invited reviews. He has been an invited lecturer at more than 500 congresses and conferences all over the world.

He received, in 2011, the Andrea Prader Prize, the highest recognition of Pediatric Endocrinology in the world.



Corso ECM



GINECOLOGIA AMBULATORIALE: DALLE SINERGIE SPECIALISTICHE ALLA SCELTA DI CURA

Venerdì 15 Marzo

15:45/18:00

Chairmanship: Boncinelli Vieri (IT) - Simoncini Tommaso (IT)

Basili Stefania (IT)

La prevenzione cardiovascolare nella donna

Lello Stefano (IT)

Il management dell'osteopenia ed osteoporosi
in menopausa

Lisotto Carlo (IT)

Eemicrania, estroprogestinici e rischio vascolare



HALL VENICE 1

08:30/09:30 SCIENTIFIC SOCIETY SYMPOSIUM (Organized by International Society of Gynecological Endocrinology - ISGE)

GONADOTROPINS AND OVULATION: FROM BASIC SCIENCE TO CLINICS

CHAIRMANSHIP: SIMONCINI TOMMASO (IT), SCHINDLER ADOLF (DE)

Devoto Luigi (CL) Role of Progesterone receptor in human ovulation

Lunenfeld Bruno (IL) 50 years of clinical use of gonadotropins -Thoughts for the future

Naftolin Frederick (US) Out of Africa: Evolution of Human Reproduction During the Great Waves of Outward Migration

09:45/11:15 PLENARY SESSION

PROGESTINS AND ANTIPROGESTINS

CHAIRMANSHIP: PETRAGLIA FELICE (IT), FOIDART JEAN-MICHEL (BE)

Bouchard Philippe (FR) Mechanisms and Classifications of Progestins, with a special emphasis on Contraception

Schindler Adolf (DE) Progestogens and thromboembolic risk

Sitruk Ware Regine (US) Ulipristal long-term effects on endometrial and breast cells

Ruan Xiangyan (CN) Different actions of progestins via progesterone receptor membrane component-1

11:45/13:15 SPONSORED SYMPOSIUM

(Sponsored by BESINS)

MICRONIZED PROGESTERONE IS SAFE AND UNIQUE IN HRT

CHAIRMANSHIP: STUDD JOHN (UK), SCHINDLER ADOLF (DE)

Gompel Anne (FR) Different impact of micronized progesterone and progestins on the breast

Schumacher Michael (FR) Novel perspective for micronized progesterone with special reference to the brain

Mueck Alfred (DE) Why is micronized progesterone and transdermal estradiol safer on cardiovascular risk: an update

13:30/15:15 LUNCH SYMPOSIUM

(Sponsored by IBSA)

FOCUS ON PROGESTERONE: THE PREGNANCY HORMONE

CHAIRMANSHIP: GENAZZANI ANDREA RICCARDO (IT), SIMON CARLOS (ES)

Genazzani Andrea Riccardo (IT) The role of progesterone in early pregnancy

De Ziegler Dominique (FR) The hidden face of progesterone, its non-pelvic effects

Tarlatzis Basil (GR) Progesterone in the Luteal support: when, how much, how long?

Facchinetti Fabio (IT) Progestogens for preterm delivery: prophylaxis or treatment?

15:45/16:15 PLENARY LECTURE

CHAIRMANSHIP: CASTELO-BRANCO CAMIL (ES)

Christiansen Claus (CH) Why should all postmenopausal women be treated the same? Identification of the right HRT/SERM, at the right dose at the right time for the right patients!

16:30/18:00 PLENARY SESSION

ENDOMETRIOSIS UP TO DATE FROM DIAGNOSIS TO THERAPIES

CHAIRMANSHIP: BEN RAFAEL ZION (IL), KIESEL LUDWIG (DE)

Petraglia Felice (IT) Medical treatments

Chapron Charles (FR) Endometriosis: the surgical management

Ebert Andreas D. (DE) Radical surgery in Deep Infiltrating Endometriosis - Complications...and pregnancies

HALL VENICE 2

08:30/09:30 MEET THE EXPERTS

PELVIC ULTRASOUNDS: THE ATIPICAL ISSUES

CHAIRMANSHIP: LUCHI CARLO (IT), KURJAK ASIM (HR)

Exacoustos Caterina (IT) 3D ultrasound evaluation of the uterine junctionale zone in pelvic endometriosis and infertility
Goldstein Steven (US) Incidental findings on pelvic ultrasound: How to handle them

09:45/11:15 SPONSORED SYMPOSIUM

(Sponsored by L.O.LI Pharma)

MYO-INOSITOL: A BREAKTHROUGH IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME AND OVULATION INDUCTION

CHAIRMANSHIP: BENVENGA SALVATORE (IT), LANZONE ANTONIO (IT)

Facchinetti Fabio (IT) PCOS: One disorder two targets. Is Myo-inositol the perfect bullet?
Lattakova Michaela (SK) Metabolic and hormonal effects of myo-inositol in women with PCOS.
Kamenov Zdravko (BG) Treatment with myo-inositol alone and in combination with clomiphene citrate in PCOS women
Freou Thomas (FR) High reward low risk: Myo-inositol the insulin sensitizer for PCOS

11:45/13:15 PLENARY SESSION

THE UNMET NEEDS IN MATERNAL-FETAL MEDICINE

CHAIRMANSHIP: FERRAZZI ENRICO (IT), KLIMEK RUDOLF (PL)

Facchinetti Fabio (IT) Pitfalls in preterm delivery prevention
Brincat Mark (MT) Progesterone & Progestogens in the prevention of Premature Labour
Regan Leslie (UK) Poor trophoblast invasion - key determinants
Carp Howard (IL) Progestogens in threatened miscarriage

15:45/16:15 PLENARY LECTURE

CHAIRMANSHIP: COUTIFARIS CHRISTOS (US)

Schenker Joseph (IL) Complications of Assisted Reproductive Technology

16:30/18:00 PLENARY SESSION

MENOPAUSE: NEW CHALLENGES, NEW SOLUTIONS

CHAIRMANSHIP: NAFTOLIN FREDERICK (US), MUECK ALFRED (DE)

Studd John (UK) Should oestrogens be first choice therapy for osteoporosis in the under 60's?
Marie Scemama Lydia (FR) Menopause, Drugs and Doctors today
Panay Nick (GB) HRT: How to solve the progestogen problem?
Pluchino Nicola (IT) Estetrol: a fetal estrogen with many opportunities: the CNS impact

HALL VENICE 3

08:30/09:30 SCIENTIFIC SOCIETY SYMPOSIUM (organized by Federazione Italiana di Sessuologia Scientifica - FISS)

SALUTE SESSUALE E SALUTE RIPRODUTTIVA

CHAIRMANSHIP: BONCINELLI VIERI (IT), FABRIZI ADELE (IT)

Fabrizi Adele (IT) La sessualità nella donna infertile

Stettini Piero (IT) Sessualità e infertilità... infertilità e sessualità

Todella Roberto (IT) La valutazione sessuologica nella coppia in cerca di gravidanza

09:45/11:15 PLENARY SESSION

SURGERY AND FERTILITY

CHAIRMANSHIP: CICCIARELLA RAFFAELE (IT), CREATSAS GEORGE (GR)

Gomel Victor (CA) The Fallopian Tube: a reappraisal

Mettler Liselotte (DE) Pro's and con's for myoma enucleation in infertility surgery

Angioni Stefano (IT) Fertility preserving surgery of endometrioma

Cela Vito (IT) Robotic in Reproductive Surgery

11:45/13:15 PLENARY SESSION

IMPLANTATION

CHAIRMANSHIP: DIEDRICH KLAUS (DE), SHOHAM ZEEV (IL)

Simon Carlos (ES) Genomics and Secretomic of Endometrial Receptivity. Clinical Translation.

Foidart Jean Michel (BE) Follicular G-CSF ,a predictive marker of embryo competence and implantation, a useful test for embryo selection

Ben Rafael Zion (IL) Prevention of OHSS

Buchholz Tina (DE) Trophoctoderm analysis for chromosomal aberrations

15:45/18:00 ITALIAN TEACHING COURSE

(Sponsored by PFIZER)

GINECOLOGIA AMBULATORIALE: DALLE SINERGIE SPECIALISTICHE ALLA SCELTA DI CURA

CHAIRMANSHIP: BONCINELLI VIERI (IT), SIMONCINI TOMMASO (IT)

Basili Stefania (IT) La prevenzione cardiovascolare nella donna

Lello Stefano (IT) Il management dell'osteopenia ed osteoporosi in menopausa

Lisotto Carlo (IT) Emicrania, estrogeni e rischio vascolare

HALL GOLDONI

08:30/09:30 SCIENTIFIC SOCIETY SYMPOSIUM

(Organized by MSRM)

MEDITERRANEAN SOCIETY FOR REPRODUCTIVE MEDICINE (MSRM)

CHAIRMANSHIP: INAUDI PIERALDO (IT), MAKRIANNAKIS ANTONIS (GR)

Messinis Ioannis (GR) Contemporary issues in ovarian stimulation

Watrelet Antoine (FR) Fertility After Surgery

Barri Pedro N. (ES) Female fertility preservation

Sefrioui Omar (YT) Management of repeated implantation failure in IVF cycles

09:45/11:15 SPONSORED SYMPOSIUM

(Sponsored by MSD)

A NEW ERA IN CONTRACEPTION: NON ORAL ADMINISTRATION

CHAIRMANSHIP: PALACIOS SANTIAGO (ES), MELIS GIAN BENEDETTO (IT)

Nicastro Benedetta (IT) Merck For Mothers

Nappi Rossella (IT) Benefits of Non Oral Contraception.

Benedetto Chiara (IT) Unwanted Pregnancies and prevention. Focus on Italy

11:45/13:15 SPONSORED SYMPOSIUM

(Sponsored by Bayer)

MODERN MENOPAUSE MANAGEMENT WHY IS PROGESTIN CHOICE SO IMPORTANT?

CHAIRMANSHIP: YU QI (CN), PANAY NICKOLAS (GB)

Gambacciani Marco (IT) Modern Menopause Management

Simoncini Tommaso (IT) The Unique Profile of Angeliq in Menopause Management

Collins Peter (GB) Latest evidence on cardiovascular outcomes and their implication for clinical practice

15:45/16:15 PLENARY LECTURE

CHAIRMANSHIP: NIESCHLAG EBERHARD (DE)

Sultan Charles (FR) Female elite athletes and hidden XY DSD

16:30/18:00 PLENARY SESSION

THE HYPOGONADAL MALE

CHAIRMANSHIP: BOUCHARD PHILIPPE (FR), BUEHLER KLAUS (DE)

Nieschlag Eberhard (DE) The Klinefelter Syndrome

Christin-Maitre Sophie (FR) Hypogonadism in male: what etiologies should we think about?

Lunenfeld Bruno (IL) An Ageing World And Its Consequences

Huszar Gabor (US) Sperm-hyaluronic acid binding score and assessment of sperm development: sperm ha-binding, total motile sperm and age attributes in 768 men

HALL CASANOVA

08:30/09:30 ORAL PRESENTATION

EARLY PREGNANCY

CHAIRMANSHIP: CARP HOWARD (IL), PAOLETTI ANNA MARIA (IT)

Novikova Vladislava (RU) The role of thrombophilia in the characteristics of the utero-placental blood flow

Shabrina Olesia (RU) Modern methods of diagnosis and treatment of abdominal pregnancy

Aleksandrova Natalia (RU) Missed abortion after assisted reproductive technologies: importance of molecular genetic and cytogenetic diagnostics

Lebedeva Olga (RU) Expression of TLR1-10 and caspase-3 alfa in human at women with early miscarriages

Schifano Martina (IT) First trimester PAPP-A plasma levels and fetal growth: correlation with uterine arteries flow and endothelial function

Mortazavi Forough (IR) Maternal Quality of life during the transition to motherhood: a longitudinal study

Ingstrup Katja (DK) Maternal bereavement in the antenatal period and oral cleft in the offspring

09:45/11:15 ORAL PRESENTATION

MENOPAUSE

CHAIRMANSHIP: SIMONCINI TOMMASO (IT), LELLO STEFANO (IT)

Huang Zhongwei (SG) Sexuality issues in postmenopausal Asian women: a significant problem?

Moreno María (MX) Sleep Disturbances In Peri- And Postmenopause. Interaction With Symptoms And Hormonal Factors

Spina Stefania (IT) Effects of progesterone and medroxyprogesterone acetate on actin remodeling and neuronal spine formation
Giannini Andrea (IT) Effect of DHEA therapy on sexual behaviour in female rats
Muscat Baron Yves (MT) Trochanteric cortical thickness and soft tissue thickness at the hip in various groups of women—new markers for postmenopausal osteoporotic hip fracture
Palla Giulia (IT) Estrogen regulates endothelial plasminogen activator inhibitor (pai-1) synthesis through c-fos and c-jun
Słopień Radosław (PL) Serum 17beta-estradiol concentration and depression symptoms presence in climacteric women.
Reis Adelina (BR) Comparison of the effect of ovariectomy (OVX) in young and old rats: body weight, blood pressure and natriuretic peptide system
Wildemeersch Dirk (BE) Acceptability of LNG-IUS combined with parenteral ERT for seamless transition through the menopause
Taavoni Simin (IR) Effect of Aromatherapy Massage on Psychological Symptoms of Iranian Postmenopausal Women: a Randomized Clinical Trial Study

11:45/13:15 ORAL PRESENTATION

ENDOCRINE DISORDERS IN THE TWO GENDERS

CHAIRMANSHIP: PLUCHINO NICOLA (IT), MILEWICZ ANDRZEJ (PL)

Mioni Roberto (IT) Insulin and body weight but not hyperandrogenism, seem involved in seasonal SERUM 25-OH-vitamin D3 Levels in subjects affected by PCOS
Pirkalani Kiumars (IR) Psychological stress causes relative infertility through direct change in the frequency pattern of GnRH release from the hypothalamus
Mancini Antonio (IT) Cervical mucus pattern and ovarian function: role in diagnosis and treatment of of subclinical hypothyroidism
Marina Ljiljana (RS) The level of dheas in women with premature ovarian insufficiency
Zektser Vita (RU) Hormonal replacement therapy in women of reproductive age with hypopituitarism
Maciel Gustavo (BR) The impact of neonatal exposure to sex steroids on ovarian folliculogenesis and on expression of genes related to apoptosis
Zelenina Tatiana (RU) Testosterone treatment in diabetic hypogonadal men
Verga Falzacappa Cecilia (IT) Thyroid hormone T3 induces ovarian function in rat granulosa cells and follicles
Ge Renshan (CN) Genomic profiling of rat progenitor Leydig cells after luteinizing hormone treatment
Hucklebridge Frank (GB) Patterns of adrenal cortisol and DHEA secretion during female adolescence: implications for psychiatric disorders.

16:30/18:00 ORAL PRESENTATION

NEW TECHNIQUES IN MEDICALLY ASSISTED PROCREATION

CHAIRMANSHIP: INAUDI PIERALDO (IT), DE ZIEGLER DOMINIQUE (FR)

Di Emidio Giovanna (IT) Detection of Reactive Oxygen Species (ROS) in discarded IVF oocytes as a model to investigate the effects of Cryotop vitrification on the redox status of oocytes from young and reproductively aged women
Suturina Larisa (RU) Antioxidant activity of follicle liquid and outcomes of ART
Sheikhi Abdolkarim (IR) Apoptotic spermatozoa removal by Magnetic-activated cell sorting improves the fertilization rate of couples treated with ICSI procedure
Vitti Maurizio (IT) Investigation of PPAR signalling in human granulosa cells (hGCs) obtained from IVF patients under different regimens of ovarian stimulation
Di Pietro Cinzia (IT) MiRNA profiling in human follicular fluid
Hammadeh Me (DE) Chromatin condensation, DNA fragmentation and apoptosis before freeze and post thaw of spermatozoa of fertile and subfertile men.
Artini Paolo Giovanni (IT) Gene expression profiles of cumulus cells obtained from women treated with different stimulation protocols.



**INTERNATIONAL SCHOOL
OF GYNECOLOGICAL
AND REPRODUCTIVE
ENDOCRINOLOGY**

THE EDUCATIONAL BRANCH OF ISGE

SUMMER SCHOOL

MALTA

JUL 14 • 19 2013

WWW.ISGESOCIETY.COM/SUMMER2013

Frontiers in Gynecological Endocrinology: From Symptoms to therapies

FORMAT OF THE SCHOOL

The activities of the school will start on Sunday afternoon and will finish the following Friday evening. The structure will include 3 hours teaching in the morning from 8.30 to 11.30 and 3 hours and an half in the afternoon (lessons from 16.30 to 19.30 and a general discussion from 13.00 to 20.00) for a total of 31 hours of formal teaching. Each day from 15.30 to 16.30 a Meet the expert session on hot topics will be held. The participation to this session will not be mandatory and the access will be for free.

★	★	★
Lessons	Spare time	MEET THE EXPERT
08.30	11.30	15.30 16.30 20.00

Each lesson will last 45 minutes plus 15 minutes for questions and answers.

Official Language

All the lessons will be in English.

No simultaneous translation will be provided.

MALTA



From its North African and Arabic influences to the Sicilian-inspired cuisine, Malta is a microcosm of the Mediterranean. Few European countries have such concentrated history, architecture and, yes, beaches in so tiny an area.

There's been an eclectic mix of influences and a roll-call of rulers over the centuries. This island nation (all 316 sq km of it, comprising the islands of Malta, Gozo and Comino) has a quirky character all of its own. From prehistoric temples, to the baroque architecture of Valletta, feasts of rabbit to festas of noisy fireworks, rattling buses to colourful fishing boats, this nation has loads of unique charm.

	HALL VENICE 1	HALL VENICE 2	HALL VENICE 3	HALL GOLDONI	HALL CASANOVA
08.15-09.15	Scientific Society Symp. Estetrol: from basic science to clinical application (organized by European Society of Gynecology - ESG)	Meet the experts Subtotal versus total hysterectomy	Scientific Society Symp. Highlights in Gynecological Endocrinology (organized by Sociedade Brasileira de Ginecologia Endócrina-Sobrage)	Oral Presentation Gynecologic diseases and imaging	Oral Presentation The male factor
09.30-11.00	Plenary session Chronic pelvic pain and comorbidities	Plenary session Oocyte	Plenary session New challenges in obstetric care	Plenary session Hormonal contraception: future and new options	Oral Presentation ART: from the lab to the clinics
11.00-11.30	Exhibit visit				
11.30-13.00	Plenary session Menopause	Plenary session Medically Assisted Procreation	Plenary session PCOS	Oral Presentation Infertility	Oral Presentation Obstetrics
13.15-15.00	Lunch Symposium Ethical aspects in reproduction	Lunch Symposium Sexuality			
15.00-15.30	Exhibit visit				
15.30-16.00	Plenary Lecture From cryopreservation of ovarian tissue to artificial ovary	Plenary Lecture Alternatives to Hysterectomy	Plenary Lecture Tribalism and reproduction in our post-darwinian society	Plenary Lecture Diagnosis first trimester	
16.00-17.30	Plenary session Primary Ovarian Insufficiency	Plenary session Contraception	Plenary session ART: from basic science to clinical application	Oral Presentation Polycystic Ovary Syndrome	Oral Presentation Endometriosis
17.30-18.00				Closing Ceremony	

15.30-16.00 Hall Venice 1

From cryopreservation of ovarian tissue to artificial ovary
Donnez Jacques (BE)

Different cryopreservation options for fertility preservation in cancer patients include embryo cryopreservation, oocyte cryopreservation and ovarian tissue cryopreservation. Embryo cryopreservation requires the patient to be of pubertal age, have a partner, and be able to undergo a cycle of ovarian stimulation. Oocyte cryopreservation is also effective, but the quality of eggs in women suffering from cancer is so far unproven, and also requires time for ovarian stimulation.

Cryopreservation of ovarian tissue is the only option available for prepubertal girls, and for woman who cannot delay the start of chemotherapy.

Around 50-60 cases of orthotopic reimplantation of frozen-thawed ovarian tissue have been reported to date and 22 live births have been achieved, yielding a pregnancy rate of more than 25%. In our department, ten women have undergone orthotopic reimplantation of cryopreserved tissue either once or twice. Restoration of ovarian function, proved by follicular development and estradiol secretion, occurred in all cases but two (absence of follicles in the frozen-thawed tissue). A time interval of 3.5 to 5 months was observed. In the literature, pregnancies were naturally obtained in 50% of cases. Graft activity was found to persist for 2.5 to 4 years. In non-pregnant patients, IVF was performed, but the quality of oocytes and embryos was not optimal.

Prognostic factors (age, previous chemotherapy) are therefore discussed.

In conclusion, fertility preservation is now a real possibility for patients whose gonadal function is threatened by radiotherapy or chemotherapy.

15.30-16.00 15 Hall Venice 2

Alternatives to Hysterectomy
Sciarra John J (US)

Alternatives to hysterectomy include myomectomy, uterine artery embolization, MRI guided focused ultrasound, endometrial ablation, the Levonorgestrel IUD, and new medical therapies. Uterine artery embolization is 80-90% effective in decreasing menorrhagia, and complications are few but occasionally are serious. Follow up of over 2,000 patients for 3 years reveals a 9.8% rate of subsequent hysterectomy and a 2.8% rate of subsequent myomectomy. MRI guided focused ultrasound is a new technique for treatment of uterine fibroids. With endometrial ablation, reduction of menstrual flow is adequate symptom control, and achievement of amenorrhea is not important. The hysterectomy rate following endometrial ablation is at least 24% within 4 years following the procedure. The Levonorgestrel IUD has proved useful in the management of menorrhagia because of the direct progestational effect on the endometrium. Transvaginal uterine artery occlusion is a treatment that is being developed but is still investigative. New medical therapies for uterine fibroids include the use of aromatase inhibitors and progesterone receptor modulators. In conclusion, while hysterectomy is 100% effective in treating benign uterine pathology, alternative methods are not. Accordingly, when considering alternatives to hysterectomy, the options should be presented to the patient, and the patient should be involved in the decision making process.

15.30-16.00 Hall Venice 3

Tribalism and reproduction in the post-darwinian world
Naftolin Frederick (US)

The evolution of an increasingly powerful prefrontal cortex in higher primates has allowed *Homo sapiens* to dominate the world. After premonitory signs of Man's escape from physical-adaptive evolution in our early great civilizations, the industrial revolution and the development of modern public health measures signaled the final ascendancy of social evolution over physical-adaptive evolution. To be sure, physical-adaptive evolution continues to be a force, but during the last three centuries humans have had their way in all but the most inhospitable areas of the Earth. Further, while asserting dominance over all other species, Man has engaged in genetic engineering on a colossal scale that has opposed physical-adaptive evolution; optical lenses to ensure vision, vaccination and antibiotics to make susceptibility to infection a minor player, harnessing the power of engines that level the field of personal strength and the application of treatments to otherwise fatal conditions (as in the case of insulin treatment of Type 1 diabetes) have given "survival of the fittest" a different meaning. Today, we die of chronic diseases rather than acute illnesses, as was the case a century ago. It is likely that social evolution will be the mechanism of survival or failure of the species in the foreseeable future.

Tribalism and reproduction are the main drivers of survival in physical-adaptive evolution. Being able to tell self from non-self and to reproduce self propel forward adaptive strains and species. While not necessary to social evolution, tribalism and reproduction are among the most deeply embedded elements in our genomic fabric and continue to be active forces in many aspects of contemporary life. In this presentation their expression and effects will be presented, mainly as an explanation of reproductive trends in our world. Exposition of these matters may lead to a better understanding of the forces in play today and furnish a guide to minimizing potentially harmful effects on the human enterprise in the future.

15.30-16.00 Hall Goldoni

Diagnosis first trimester
Nicolaidis Kypros H. (UK)



Donnez Jacques

Jacques Donnez was born in Tournai (Belgium) on 16 July, 1047. He studied at the Catholic University of Louvain. He defended his PhD thesis in 1984, entitled "The fallopian tube: normal and pathological histophysiology".

He became Full Professor and Head of the Department Gynaecology and Andrology in 1986. He also founded the Infertility Research Unit of the Catholic University of Louvain in 1986. He has focused his research activities on three main topics: tubal infertility, endometriosis and finally, ovarian cryopreservation and transplantation. He published over 600 original articles in peer-review journals. Prof. Donnez is the first President of the International Society for Fertility Preservation and has been elected in February 2009 at the Royal Belgian Academy of Medicine.



Sciarra John J.

John J. Sciarra, MD, PhD is Professor and Chair Emeritus of the Department of Obstetrics and Gynecology at Northwestern University Medical School. In Relation to international activities, Dr. Sciarra served as the president of the International Federation of Gynecology and Obstetrics (FIGO) and is editor emeritus

of the International Journal of Gynecology and Obstetrics. At the world health organization (WHO), he served as Chair of the scientific and ethical review committee of the special program for research, education and research training in human reproduction. Dr. Sciarra is the Editor-in-Chief of the Global Library of Women's Medicine, that provides open-access educational information for physicians in over 170 countries.



Naftolin Frederick

Frederick Naftolin, MD, D. Phil. was Chairman of Obstetrics and Gynecology at McGill University, 1975-8 and Yale University, 1978-2000. He has been Professor and Head of Reproductive Biology Research at New York University since 2005. Dr. Naftolin's scientific contributions include the observation of gonadotrophin

binding by the ovary, response to sheep gonadotrophin releasing hormone (GnRH), that the blood pre-ovulatory estrogen peak precedes the gonadotrophin surge, discovery of estrogen synthesis by brain tissue, discovery of the pulsatile pattern of gonadotrophin in men and women, discovery of estrogen-induced hypothalamic synaptic plasticity (EISP) and its role in GnRH/gonadotrophin feedback control, and, the existence and action of the ovarian renin-angiotensin system (OVRAS). Most recent contributions include DHEA- and sex steroid-regulated NCAM polysialylase in human blood vessel endothelium inhibits NCAM's tethering of monocytes to human vascular endothelium, and, the role of ezrin in cell transformation and cancer pathogenesis and treatment.



Nicolaides Kypros H.

Professor of Fetal Medicine, King's College, London, Professor of Fetal Medicine, University College, London.

Founder and Chairman of the Fetal Medicine Foundation. This charity was set up in 1995.

HALL VENICE 1

08:15/09:15 SCIENTIFIC SOCIETY SYMPOSIUM

(organized by European Society of Gynecology)

ESTETROL: FROM BASIC SCIENCE TO CLINICAL APPLICATION

CHAIRMANSHIP: SERFATY DAVID (FR), ALMEIDA-SANTOS ANA TERESA (PT)

Foidart Jean-Michel (BE) Estetrol the fourth human estrogen

Apter Dan (FI) Efficacy, tolerance and bleeding pattern of estetrol containing contraceptives

Genazzani Andrea R. (IT) Estetrol: a fetal estrogen with serum activities in brain and breast

09:30/11:00 PLENARY SESSION

CHRONIC PELVIC PAIN AND COMORBILITIES

CHAIRMANSHIP: SISELES NESTOR (AR), CARUSO SALVATORE (IT)

Graziottin Alessandra (IT) Mast cell, chronic inflammation, pain and depression

Stanghellini Vincenzo (IT) Chronic Pelvic Pain and gastrointestinal Comorbidities

Bornstein Jacob (IL) Local Provoked Vulvodynia (Vestibulitis): Hyperinnervation associated with mast cell activation - Pathogenesis and treatment

11:30/13:00 PLENARY SESSION

MENOPAUSE

CHAIRMANSHIP: BIRKHAUSER MARTIN (CH), SITRUK-WARE REGINE (US)

Stevenson John (GB) HRT and coronary heart disease: cause or cure

Castelo-Branco Camil (ES) Aging and the immune response

Genazzani Andrea Riccardo (IT) Menopausal symptoms as comorbidity factors for brain aging

Christiansen Claus (CH) The coupling of bone resorption to bone formation and cartilage turnover to bone turnover: A possibility for dual action therapies?

13:15/15:00 LUNCH SYMPOSIUM SPECIAL SESSION

ETHICAL ASPECTS IN REPRODUCTION

CHAIRMANSHIP: SCIARRA JOHN J. (US), BARRI PEDRO (ES)

Schenker Joseph (IL) Jewish Perspectives

Serour Gamal (EG) Ethical Issues in Human Reproduction Islamic Perspectives

Lanzone Antonio (IT) Catholic Perspective

Birkhauser Martin (CH) Protestant Perspectives

15:30/16:00 PLENARY LECTURE

CHAIRMANSHIP: SCHENKER JOSEPH (IL)

Donnez Jacques (BE) From cryopreservation of ovarian tissue to artificial ovary

16:00/17:30 PLENARY SESSION

PRIMARY OVARIAN INSUFFICIENCY

CHAIRMANSHIP: PALACIOS SANTIAGO (ES), STEVENSON JOHN C. (GB)

Panay Nick (GB) Primary Ovarian Insufficiency - evolution of a global database

Vujovic Svetlana (RS) EMAS position statement on the Premature Ovarian Insufficiency

Barri Pedro N. (ES) Reproductive options of patients with primary or Premature Ovarian Insufficiency

Mueck Alfred (DE) HRT after ovarian cancer

HALL VENICE 2

08:15/09:15 MEET THE EXPERTS

SUBTOTAL VERSUS TOTAL HYSTERECTOMY

CHAIRMANSHIP: GOMEL VICTOR (CDN), DONNEZ JAQUES (BE)

Mettler Liselotte (DE) Subtotal versus total hysterectomy

Ussia Anastasia (IT) Subtotal versus total hysterectomy

09:30/11:00 PLENARY SESSION

OOCYTE

CHAIRMANSHIP: SHOHAM ZEEV (IL), SIMON CARLOS (ES)

Patrizio Pasquale (US) New tools to assess oocyte competence

Tan Seang Lin (CA) IVM Treatment for difficult patients

Artini Paolo (IT) Maintenance of biological competence after oocyte vitrification

Veiga Anna (ES) Pluripotent Stem Cells and regenerative Medicine

11:30/13:00 PLENARY SESSION

MEDICALLY ASSISTED PROCREATION

CHAIRMANSHIP: PATRIZIO PASQUALE (US), ALVIGGI CARLO (IT)

Kovacs Gabor (AU) Gender Selection

Shoham Zeev (IL) Practice vs. Science

Schmutzler Andreas (DE) Polar body biopsy with fish and chips

13:15/15:00 LUNCH SYMPOSIUM

SEXUALITY

CHAIRMANSHIP: STUDD JOHN (UK), GRAZIOTTIN ALESSANDRA (IT)

Palacios Santiago (ES) Role of SERMs and SPERMs in female sexuality

Nappi Rossella (IT) Uncomfortable conversation on sexual issue at menopause

Panay Nick (GB) Testosterone: HSDD and cardiovascular impact

Caruso Salvatore (IT) Quality of sexual life of women on oral contraceptive continued-regimen

15:30/16:00 PLENARY LECTURE

CHAIRMANSHIP: METTLER LISELOTTE (DE)

Sciarrà John J (US) Alternatives to Hysterectomy

16:00/17:30 PLENARY SESSION

CONTRACEPTION

CHAIRMANSHIP: DE MELO NILSON ROBERTO (BR), KHOMASSURIDZE ARCHIL (GE)

Skouby Sven (DK) LARC

Sitruk Ware Regine (US) A vaginal ring to deliver Progesterone Receptor Modulators for contraception

Serfaty David (FR) Emergency contraception: ulipristal acetate or levonorgestrel?

Siseles Nestor (AR) What is the impact of the use of contraceptive methods on the health in the menopausal transition?



— 16 —
WORLD CONGRESS
OF GYNECOLOGICAL
ENDOCRINOLOGY ♀
IV CONGRESSO ISGE ITALIA



MARCH 5-8 2014 — FIRENZE ITALY
WWW.ISGESOCIETY.COM/ISGE2014

HALL VENICE 3

08:15/09:15 SCIENTIFIC SOCIETY SYMPOSIUM (organized by Sociedade Brasileira de Ginecologia Endócrina-SOBRAGE)

Highlights in Gynecological Endocrinology

CHAIRMANSHIP: CASOY JULIO (BR), MAIA HUGO (BR)

Maia Jr. Hugo (BR) Natural NF-Kappa.b inhibitors associated with continuous oral contraceptives for the treatment of endometriosis

Bonassi Rogerio (BR) Clinical trials with extended regimens of hormonal contraception in Brazil

Magalhaes Jarbas (BR) Intrauterine system with levonorgestrel for the treatment of menorrhagia

Maia Jr. Hugo (BR) Androgen replacement therapy in late menopause and its impact on inflammatory markers

Pellini Eliano (BR) Menopause is far from being the sunset of sexuality

Casoy Julio (BR) Concluding remarks

09:30/10:00 PLENARY SESSION

NEW CHALLENGES IN OBSTETRIC CARE

CHAIRMANSHIP: CARP HOWARD (IL), REGAN LESLIE (GB)

Uzan Serge (FR) Cancer in pregnancy: a challenging conflict of interest

Benedetti Panici Pierluigi (IT) Chemotherapy in pregnancy: fetal and maternal effects

Klimek Rudolf (PL) Prevention of premature deliveries

Mannella Paolo (IT) Fetoplacental endothelial dysfunction and fetal growth restriction

11:30/13:00 PLENARY SESSION

PCOS

CHAIRMANSHIP: SKOUBY SVEN O. (DK), VUJOVIC SVETLANA (RS)

Strauss III Jerome (US) The Genetics of Polycystic Ovary Syndrome: from genome-wide association to molecular mechanisms

Genazzani Alessandro (IT) PCOS as a metabolic impaired disease

Tarlatzis Basil (GR) Infertility treatment in women with PCOS

Gurgan Timur (TR) Can IVM ever replace IVF in PCOS patients?

15:30/16:00 PLENARY LECTURE

CHAIRMANSHIP: SEROUR GAMAL I. (EG)

Naftolin Frederick (US) TRIBALISM AND REPRODUCTION IN THE POST-DARWINIAN WORLD

16:00/17:30 PLENARY SESSION

ART: FROM BASIC SCIENCE TO CLINICAL APPLICATION

CHAIRMANSHIP: TAN SEANG LIN (CDN), VEIGA ANNA (ES)

Coutifaris Christos (US) Singletons and ART: what does the science tell us?

Buehler Klaus (DE) LH supplementation only in older women?

Alvigi Carlo (IT) ARE THESE DIFFERENT hMGs?

Ferraretti Anna Pia (IT) Ovarian response to CHO: the normo responders

HALL GOLDONI

08:15/09:15 ORAL PRESENTATION

GYNECOLOGIC DISEASES AND IMAGING

CHAIRMANSHIP: MUECK ALFRED (DE), MANNELLA PAOLO (IT)

Wong Alice Wai Yee (GB) Evaluation of congenital uterine anomalies: value of conventional two-dimensional ultrasound and three-dimensional ultrasound

Grigore Mihaela (RO) The benefit of 3D ultrasound in the diagnosis of adenomyosis
 Grigore Mihaela (RO) 3D ultrasound versus hysteroscopy in the diagnosis of uterine abnormalities
 Iodice Veronica (IT) Technical and clinical development of a computer-assisted three-dimensional imaging system for uterine fibromatosis surgery
 Jurisic Zaklina (RS) 3D Multislice Ultrasound in Uterine Anomalies Detection
 Jurisic Aleksandar (RS) 3D multislice saline infusion sonography in preoperative evaluation of endometrial cavity
 Res Muravec Ursula (SI) Evaluation of tubal patency with 2D-3D ultrasound in an outpatient setting-HyCoSy

09:30/11:00 PLENARY SESSION

HORMONAL CONTRACEPTION: FUTURE AND NEW OPTIONS

CHAIRMANSHIP: SERFATY DAVID (FR), DEVOTO LUIGI (CL)

Coelingh Bennink Herjan (NL) Clinical effects of repairing the loss of testosterone caused by the pill
 De Melo Nilson Roberto (BR) Future of hormonal contraception
 Khomassuridze Archil (GE) Noncontraceptive possibilities of hormonal contraceptives
 Del Pup Lino (IT) Could The Noregestrol Acetate/ Estradiol hormonal oral contraceptive reduce breast cancer risk?

11:30/13:00 ORAL PRESENTATION

INFERTILITY

CHAIRMANSHIP: NAPPI ROSSELLA (IT), DEL PUP LINO (IT)

Onat Güliz (TR) A study related to improve a scale to determine the infertile women's exposure to violence
 Demaliaj Eliona (AL) Role of hyperprolactinemia in fertility.
 Koizumi Tomoe (JP) The acceptance of infertility; infertility stress, stress coping behavior, marital relationships and personality development
 Chausiaux Oriane (GB) Are BMI, age, FSH and AMH good markers of spontaneous conception in infertile women?
 Chausiaux Oriane (GB) The role of expectant management in treatment of couples with unexplained infertility.
 D'aniello Antimo (IT) D-Aspartic acid is involved in human reproduction
 Paiva Sara (BR) Promoting self-awareness and reflection through an experiential Mind-Body Skills Program for women with infertility-related stress

15:30/16:00 PLENARY LECTURE

CHAIRMANSHIP: UZAN SERGE (FR)

Nicolaidis Kypros (UK) Diagnosis first trimester

16:00/17:30 ORAL PRESENTATION

POLYCYSTIC OVARY SYNDROME

CHAIRMANSHIP: CARUSO SALVATORE (IT), STOMATI MASSIMO (IT)

Gonzalez Deyarina (GB) Loss of WT1 expression in the Endometrium of Infertile PCOS Patients: A Hyperandrogenic Effect?
 Ricchieri Federica (IT) Myo-inositol modulates insulin and LH secretion in normal weight patients with polycystic ovary syndrome (PCOS)
 Del Ghianda Scilla (IT) Dyslipidemia and Polycystic Ovary Syndrome
 Aziz Mubeena (DK) Polycystic Ovary Syndrome: endothelial dysfunction and low-grade inflammation according to phenotypes
 Brincat Mark P (MT) Anti-Mullerian hormone - its value in patients with polycystic ovarian syndrome
 Chebotnikova Tatiana (RU) Polycystic ovary syndrome, obesity and anovulatory infertility: weight loss effect
 Pirkalani Kiumars (IR) PCOD is a physiological adaptive reaction to prevent multiple pregnancies: Studies on 10 large families

and 44 single cases with PCOD with a mechanism guided approach

Ruban Katerina (Ua) Neuroendocrine disorders in pathogenesis of hypothalamus-pituitary- ovarian dysfunction in patients with PCOS and its treatment

17:30/18:00 CLOSING CEREMONY

HALL CASANOVA

08:15/09:15 ORAL PRESENTATION

THE MALE FACTOR

CHAIRMANSHIP: ARTINI PAOLO G. (IT), CHRISTINE-MAITRE SOPHIE (FR)

Cassuto Nino (FR) Follow up of spermatozoon selected at high magnification in assisted reproductive technologies: embryo development and outcome.

Hammadeh Me (DE) Homocysteine and malondialdehyde (MDA) levels in seminal fluid and their influence on sperm quality

Mancini Antonio (IT) Antioxidant effects of coenzyme q10 oral supplementation on seminal fluid of infertile patients with varicocele

Riccio Teresa (IT) Comparison between ejaculated and testicular spermatozoa in cryptozoospermic men. Which is the best strategy?

Cursio Elisabetta (IT) No difference in live birth rate after TESE+ICSI with fresh or frozen testicular patients with non obstructive azoospermia.

Montik Nina (IT) Predictive value of doppler sonographic parameters and serum markers in IVF and ICSI cycles.

09:30/11:00 ORAL PRESENTATION

ART: FROM THE LAB TO THE CLINICS

CHAIRMANSHIP: GURGAN TIMUR (TR), RUAN XIANGYAN (CN)

Chappel Scott (US) From Oocyte Fertilization to Implantation: Role of Mitochondria

Capalbo Antonio (IT) Comprehensive molecular karyotyping analysis of 650 human blastocysts in relation to embryo morphology, time of development and gender

Artini Paolo (IT) Multicenter observational study on practices of blasocyst culture in Italy following modifications in IVF law

Peresada Olga (BY) Forming a Group of Women under In Vitro Fertilization Program with the Risk of Cardiovascular Disease

Feitosa Weber (US) Small ubiquitin-regulated protein (SUMO) dynamics during mouse pre-implantation embryo development

Selvaraj Priya (IN) Sequential transfer in ART in the era of single embryo transfer: indications and outcomes of treatment cycles.

Selvaraj Priya (IN) ART outcomes in premature ovarian failure: changing perspectives from tubal procedures to sequential transfers

Ponce Pedro (MX) Damage to sperm chromatin with the presence of leukocytes in the semen samples: Correlation of two tests for the evaluation of male factor in infertile couples

Lau Matthew (SG) Overnight maturation of a metaphase I oocyte retrieved from a natural cycle using human tubular fluid: a case report

11:30/13:00 ORAL PRESENTATION

OBSTETRICS

CHAIRMANSHIP: UZAN SERGE (FR), BENEDETTI PANICI PIERLUIGI (IT)

Gupta Akruti (UA) Prevention of Premature delivery through Pre-conceptual prophylaxis of pre-eclampsia.

Skolarikos Panagiotis (GR) Cholestasis during two different pregnancies in a woman with deficient immunological profile – Case report

Londero Ambrogio P (IT) Placental expression of p53 and p21 in pregnancies affected by late pre-eclampsia and controls

Lebedeva Olga (RU) Expression of antimicrobial peptides after caesarian section and vaginal birth
Zektser Vita (RU) Pregnancy and maternity in patient with diabetes mellitus type 1, hypothyroidism, craniopharyngioma and hyperprolactinemia (clinical case)
Londero Ambrogio P (IT) Second trimester amniotic fluid and maternal plasma concentrations of adiponectin, leptin and glucose metabolism in women who will develop gestational diabetes mellitus and controls
Procopciuc Lucia Maria (RO) Fetal APOE genotype influences maternal lipid profile and the severity of high risk pregnancy preeclampsia. Interaction with maternal genotypes as a modulating risk factor in preeclampsia
Taavoni Simin (IR) Effect of Sacrum- Perinea Moisture Thermotherapy on Active Phase of Physiologic Labor: a Randomized Control Trial Study
Gungor Ilkay (TR) Factors influencing maternal satisfaction during birth and postpartum hospital stay

16:00/17:30 ORAL PRESENTATION

ENDOMETRIOSIS

CHAIRMANSHIP: BORNSTEIN JACOB (IL), USSIA ANASTASIA (IT)

Rani Aghila (IN) Differential expression of pattern recognition molecules on human endometrial mesenchymal stem cells
Konrad Lutz (DE) Stromal Cells in the Endometrium and Endometriosis
D'Agostino Giulia (IT) The impact of surgery on ovarian reserve in the treatment of endometrioma
Malejczyk Jacek (PL) Effect of microRNA on deregulation of tissue remodeling in endometriosis.
Guedes Ernesto (BR) Treatment of urinary endometriosis with goserelin or dienogest: 12 years follow up
Dentillo Daniel (BR) Deregulated genes in endometriotic lesions can be responsible for malignant transformation?
Brincat Mark (MT) Endometriosis and Menstrual Disorders
Artymuk Natalia (RU) Gene polymorphisms of estrogen metabolism in adenomyosis
Bakkum Erica (NL) Different surgical techniques to reduce post-operative adhesion formation: a systematic review and meta-analysis

A photograph of a Venetian canal with gondolas and historic buildings. The scene is captured from a low angle, looking down the canal. In the foreground, the ornate prow of a gondola is visible, featuring a red and gold decorative pattern. In the middle ground, another gondola with several passengers and a gondolier is moving away. The canal is flanked by multi-story brick buildings with arched windows and doorways. A small stone bridge is visible in the background. The water is calm and reflects the surrounding architecture.

15th world
congress
on human
reproduction

Venezia Italy,
Hilton Molino Stucky
13/16 March 2013

Posters

BCGIP COGI®

The World Congress on

**BUILDING CONSENSUS OUT OF CONTROVERSIES
IN GYNECOLOGY, INFERTILITY AND PERINATOLOGY**

ISTANBUL, TURKEY • MAY 30 - JUNE 2, 2013

CO-CHAIRPERSONS

**Hasan Ilkova, Turkey
Oktay Kadayıfçı, Turkey**

**Riza Madazli, Turkey
Ahmet Baschat, USA
Moshe Hod, Israel**

**Victor Gomel, Canada
Zeev Shoham, Israel**



BCGIP COGI®

The 5th Asia Pacific Congress on

**BUILDING CONSENSUS OUT OF CONTROVERSIES
IN GYNECOLOGY, INFERTILITY AND PERINATOLOGY**

SHANGHAI, CHINA • NOVEMBER 21-24, 2013

HONORARY PRESIDENT

Jinghe Lang, China

CO-CHAIRPERSONS

**Tony Duan, China
Moshe Hod, Israel**

**Jie Qiao, China
Zeev Shoham, Israel**

**Huixia Yang, China
Qi Yu, China**

www.cogi.org

Contact us: bcgip-cogi@comtecmed.com

Ordered by poster presenter's surname.

* = Presenter of the poster

1. Prevalence and Constancy of Postpartum Depression Self-reporting Over Twelve Weeks Post-partum and Psycho-socio-demographic Predictors
Abdollahi F.* (IR)
2. Psychosocial factors associated with semen quality among infertility men in Malaysia
Abdul Wahab A.* (MY)
3. Comparison of success outcome between ivf and icsi in infertile malaysian women
Abdul Wahab A.* (MY)
4. Small Amount of Testosterone Administration Improves Ovarian Response to Exogenous Gonadotropin Stimulation
Aisaka K.* (JP), Hiraike H., Hyodo H., Obata S., Miyamoto Y., Hiraike O., Hyodo H.
5. Serum Leptin Levels in Polycystic Ovary Syndrome: Correlation with Clinical and Hormonal Parameters
Aleisa N.* (SA)
6. Efficacy of the treatment the simple endometrial hyperplasia without atypia with gonadotropin-releasing hormone agonists in women of reproductive age with morbid obesity
Artymuk N.* (RU), Shakirova E.
7. Impact of misoprostol (PgE1) on pregnancy rate after intrauterine insemination
Asherkaci H.* (LY), Danfour M.
8. How is the endometrial apoptosis/proliferation balance in the polycystic ovary syndrome during proliferative phase?
Baracat E.* (BR), Simões R., Baracat M., Maciel G., Junior J.
9. Effects of metoclopramide-induced hyperprolactinemia on the content of uterine sulfated glycosaminoglycans of ovariectomized mice after treatment with steroid sex hormones
Baracat E.* (BR), Teixeira Gomes R., C., Simoes R., Baracat M., Soares Jr J.
10. A role of HLA-G polymorphism in spontaneous abortion in Polish couples.
Nowak I.* (PL), Barcz E., Malinowski A., Wilczyński J., Wagner M., Wiśniewski A., Kuśnierczyk P.
11. Sexual behavior, contraceptive use and fertility of female students in Transbaikal region of Russia
Belokrinskaya T.* (RU), Frolova N., Belozertceva E., Ionushene S.
12. Preconception screening of young healthy women for sexually transmitted infections
Belokrinskaya T.* (RU), Frolova N., Shipulina E., Gevorkyan N.
13. Modification of dietary behavior of women during the menstrual cycle
Ben Slama C.* (TN), Kammoun I., Hamza N., Makni N., Bouchrit K., Turki Z.
14. Prolactinoma: clinical, biological and radiological presentation
Ben Slama C.* (TN), Haouat E., Ben Salem L., Makni N., Maiza M., Abdesselem H.
15. Soyben extract biotransformed by fungus induces cell death in breast cancer
Bianchini F.* (BR), Fumagalli H., Stocco B., Toledo K., Fortes V., Fonseca M., Torqueti M.
16. Effects of the association of drospirenone 3 mg and ethinylestradiol 20 mcg in an extended regimen on menstrual-related symptoms: a randomized, comparative study
Bonassi Machado R.* (BR), Badalotti M., Ferriani R., Nahas E., Guazelli C., Maia Jr H.

17. Bleeding patterns and the management of irregular bleeding during the use of an oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in an extended regimen
Bonassi Machado R.* (BR), Pompei L., Andrade R., Del Debbio S., Wender M., Maia Jr H.
18. Hysterosalpingography and laparoscopy in the diagnosis of tubal occlusion in infertile women
Brankovic S.* (RS), Nejkovic L.
19. Uterus septus- pregnancy after the treatment
Brankovic S.* (RS), Nejkovic L., Vasiljevic M.
20. Obstetric outcome after laparoscopic myomectomy
Breda E.* (IT), Borgato S., D'Agostino G., Codroma A., Borghero A., Litta P.
21. The role of ulipristal* (Esmya, PregLem) in association with a LNG IUS (Mirena) in the treatment of fibroids associated with menorrhagia in a community gynaecology setting- A "proof of concept" pilot study
Briggs P.* (GB)
22. Chemoprevention of Breast Cancer
Brincat M.* (MT)
23. The Role of Progesterone Supplementation in IVF
Brincat M.* (MT)
24. Spontaneous pregnancy rate after hysteroscopic polypectomy.
Bueloni Dias F.* (BR), Dias D., Dias R., Petri-Nahás E., Nahás-Neto J., Leite N., Modotte W.
25. Improvement of sperm viability after cryopreservation of human spermatozoa by antioxidant supplementation
Bungum M.* (SE), Bungum A., Silver N.
26. The impact of male overweight on semen quality and outcome of assisted reproduction
Bungum M.* (SE)
27. The impact of Bacterial Vaginosis(BV) , Trichomonas Vaginalis (TV) and vaginal acidity on pregnancy outcome
Bylykbashi e.* (AL), Kosturi E., Demaliaj E., Rugeja A., Bylykbashi I.
28. Possible connection between bacterial Vaginosis (BV) and Cin.
Bylykbashi E.* (AL), Demaliaj E., Kosturi E., Rugeja A., Bylykbashi I.
29. Patients with hypogonadotropic hypogonadism having ART: is the obstetric outcome better?
Caragia A.* (GB), Mohamed M., Vlismas A., Talebi Chahvar S., Al-Shawaf T., Sabatini L.
30. Awareness of menopausal symptom and hormone replacement therapy in Korean postmenopausal women
Chae H.* (KR), Kim S., Kang B., Park H., Lee S., Lee E.
31. Effects of drospirenone 2mg with 17 β -estradiol 1mg on blood pressure, body weight and lipid profile in postmenopausal Korean women
Chae H.* (KR), Kim S., Kang B., Kwon S., Lee K.
32. Decidualization of fetal Bone marrow derived mesenchymal stem cells (BMSCs) is gender-dependent
Tan C.* (SG), Lee Y., Tan H., Choolani M., Griffith L., Chan J.
33. Intra-uterine growth restriction in women with thalassemia minor
Chetcuti D.* (MT), Brincat M., Scerri C., Tsar O.
34. Second look at ovarian carcinoma
Chetcuti D.* (MT), Vassallo M., Mamo J., Aquilina A., Refalo M.
35. Borderline Ovarian Tumours
Chetcuti D.* (MT), Vassallo M., Mamo J., Degaetano J., Micallef Fava A.
36. Distribution of high-risk human papillomavirus genotypes in old age women
Choi H.* (KR), Kang W., Kim S., Nam J., Park C.
37. Factors associated with the laterality of recurrent endometrioma after conservative surgery
Choi D., Kim H., Yoon B., Lee D.
38. Effects of long-term post-operative oral contraceptive use for the prevention of recurrence on bone mineral density in young women treated with endometrioma
Choi D., Kim H., Yoon B., Lee D.
39. Robotic myomectomy: Comparison with laparoscopy and laparotomy
Chung Y.* (KR), Kim M., Kwak S.

40. Efficacy and safety of a nutraceutical combination in premenstrual syndrome
Cianci A.* (IT), Benvenuti C., De Leo V.
41. Fetal Jarcho-Levin syndrome - prenatal diagnosis and perinatal care in a patient with multiple large leiomyomas
Cirstoiu M.* (RO), Munteanu O., Cirstoiu C.
42. The role of postoperative bisphosphonates therapy in patients with hip fractures related to osteoporosis of menopause
Cirstoiu M.* (RO), Munteanu O., Cirstoiu C.
43. Endometrial polyp unique - Consequently Ureaplasma urogenitalis; cause of infertility
Cotarcea S.* (RO), Stefanescu D.
44. Congenital ectropion-risk factor in cervical lesions
Cotarcea S.* (RO), Stefanescu D.
45. Compare sonographic tubal patency evaluation by three-dimensional contrast imaging with classical hysterosalpingography
Cristian V.* (RO), Carmen C., Anca B., Alice V.
46. Females transplanted with ovarians subjected to hypoxic preconditioning shows impair of ovarian function
Damous I.* (BR), Nakamuta J., Maciel G., Soares Jr J., Simões R., Montero E., Krieger J., Baracat E.
47. Rat adipose tissue-derived stem cells can be used during ovarian graft without affect ovarian function
Damous L.* (BT), Nakamuta J., Maciel G., Soares Jr J., Simoes R., Montero E., Krieger J., Baracat E.
48. Effect of caffeine, kallikrein and pentoxifylline on activation of frozen bovine sperm motility
Danfour M.* (LY), Galewan F., Asherkaci H.
49. The expressions of CD200 and CD200R molecules on myeloid and lymphoid dendritic cells in pre-eclampsia and normal pregnancy.
Darmochwal-Kolarz D.* (PL)
50. Thyroid function in women undergoing to controlled ovarian hyperstimulation
Del Ghianda S.* (IT), Benelli E., Ruggiero M., Artini P., Loconte E., Simoncini T., Vitti P., Tonacchera M.
51. Fertility preservation in lymphoma patients undergoing high dose chemotherapy and bone marrow transplantation with gn rh agonist
Del Pup L.* (IT)
52. Interaction between metoclopramide and sex steroids in serum prolactin measurement in female mice
Do Amaral V.* (BR), Rosa Maciel G., Júnior J., Carvalho K., Marcondes R., Baracat E.
53. Effectiveness of Laparoscopy in improving pregnancy rates in infertile women.
ELBAREG A.* (LY), Elmahashi M.
54. The effectiveness of hysteroscopy in the management of endometrial pathology
ELBAREG A.* (LY), Elmahashi M., Essadi F.
55. The Effect of New Turkish Legislation for compulsory single embryo transfer/double embryo transfer on ART results in a University IVF Center
Erdem A.* (TR), Gümüşlü S., Karabacak O., Ercan D., Erdem M., Oktem M., Bozkurt N.
56. The contraceptive methods habits among women aged 16 - 49 in I.Vasaraudze's Private Clinic Ltd.
Vasaraudze I., Rezeberga D., Lejnicks A., Erts R.* (LV)
57. Vitrification of human ovarian tissue
Fabbri R.* (IT), Magnani V., Macciocca M., M., Parazza I., Vicenti R., Pasquinelli G., Venturoli S.
58. Assessment of mitochondrial bioenergetic potential and oxidative stress on human ovarian tissue
Fabbri R.* (IT), Vicenti R., Martino N., Parazza I., Macciocca M., Magnani V., Pasquinelli G., Venturoli S.
59. Effects of melatonin on rat uterine apoptosis after submitting to continuous light period
Ferreira C.* (BR), Carvalho K., Paiotti A., Oshima C., Maganhin C., Simões M., Baracat E., Soares Júnior J.
60. The relationship between androgens and adipokines in polycystic ovary syndrome
Albu A., Florea S., Radian S., Fica S.* (RO)
61. Utilization of long-acting reversible contraceptive methods in the UK in 2004–2010
García Rodríguez L., Cea-Soriano L.* (ES), Wallander M., Andersson S., Filonenko A.

62. Direct Costs of Unintended Pregnancy in Spain
Lete I., Hassan F., Chatzitheofilou I., Mendivil J., Bofill A., Restovic G., Arbat A., Filonenko A.* (GB)
63. Erbium laser treatment for early stages of stress urinary incontinence (SUI) and vaginal relaxation significantly improves pelvic floor function.
Fisticonic I.* (HR), Findri Gustek S., Sorta Bilajac Turina I., Fisticonic N., Fisticonic M.
64. Topiramate treatment in obese women with PCOS and insulin resistance
Ciotta L., Andò A., Stracquadanio M., Formuso C.* (IT)
65. Breast diseases and oral contraception treatment
Stracquadanio M.* (IT), Ciotta L., Formuso C., Carbonaro A.
66. ACETYL-L-CARNITINE in the treatment of patients with weight-loss related to hypothalamic amenorrhea
Ciotta L., Stracquadanio M.* (IT), Formuso C., Andò A., Teodoro M., Leanza V., Zarbo G.
67. Apoptosis analysis in adrenal cortex of pregnant female mice exposed to atmospheric pollution
Fuchs L.* (BR), Gonçalves T., Silva J., Garcia N., Simões R., Carvalho K., Veras M., Maciel G., Saldiva P., Soares Júnior J., Baracat E.
68. Thin endometrium is related to low implantation rate of the patients after conservative treatment for endometrial cancer or atypical complex endometrial hyperplasia
Fujimoto A.* (JP), Ichinose M., Morishima K., Tsutsumi R., Harada M., Hirata T., Oishi H., Osuga Y., Yano T., Kozuma S.
69. Single incision laparoscopic ovarian drilling combined with immature oocyte retrieval, followed by IVM-ICSI and successful pregnancy
Fujimoto A.* (JP), Hirata T., Ooi N., Watanabe Y., Morishima K., Harada M., Oishi H., Osuga Y., Yano T., Kozuma S.
70. Estradiol levels is crucial in the implantation?
Ganzabal T.* (ES), Jimenez R., Barrenetxea G.
71. Uterine leiomyomas, atypical leiomyomas and leiomyosarcomas: Frizzled-1, BMP-4 and Gremlin-1 differential proteins expression
Garcia N.* (BR), Bozzini N., Cunha I., Soares F., Maciel G., Baracat E., Carvalho K.
72. Alterations in metabolic relations and adiposity during and after cigarette smoke exposition, in young female and male mice
Gaspar Reis R.* (BR), C.C. C., Aguiar E., Magdalena T., Albuquerque K., Alves S., Villaça Y., Souza É., Nascimento-Saba C.
73. A successful pregnancy in a case of maternal thrombophilia.
Gauci Grech H.* (MT)
74. Obstetric outcome after LEEP (Low Electrical Excision Procedure) of the cervix, in women with CIN 2 and CIN3.
Gjyrdedi D.* (AL)
75. The low molecular weight heparin in patients with implantation failure
Godoy H.* (MX), Mamani A., Cedillo L., Falcon J., Ponce P., Alvarado H.
76. Impact of the human egg fertilization techniques in early embryonic development
Ponce P., Godoy H.* (MX), Mamani A., Cedillo L.
77. Proteomic approach in the identification of fertility pattern in seminal plasma of fertile men
Milardi D., Grande G.* (IT), Vincenzoni F., Pontecorvi A., Castagnol M., Marana R.
78. Reproductive status in men and women after treatment for brain tumors and leukemia in childhood.
Gubernatorova E.* (RU), Pavlova M., Kaznacheeva T., Melnichenko G., Mazerkina N., Sych Y.
79. Elafin expression is reduced in hydrosalpinx
Guedes Neto E.* (BR), Fuhrich D., Savaris R.
80. Screening human and rat 17beta-hydroxysteroid dehydrogenase inhibitors to identify potential endocrine disruptors
Guo J.* (CN), Chu Y., Lian Q., Ge R.
81. Characteristics of PCOS as the changes of diet pattern for a decade in Korea
Han A.* (KR), Lee T., Chun S., Cho E.
82. The prevalence of sexual dysfunction among female in a tertiary hospital in Malaysia
Hassan J.* (MY), Lin T., Sulaiman S., Darus A.

83. The effect of herbal drug on menopausal symptoms
Hejazi S.* (IR)
84. Trefoil factor 3 – a new player in clinical and experimental endometriosis?
Henze D.* (DE), Gashaw I., Hornung D., Agueusop I., Machens K., Schmitz A., Zollner T., Döcke W.
85. Depression in the peripartum period in association with salivary cortisol levels
Iliadis S.* (SE), Hellgren C., Papadopoulos F., Sylven S., Sundström Poromaa I., Skalkidou A.
86. Humoral autoimmunity and reproductive disorders
Ilovayskaya I.* (RU), Zektser V., Keda Y., Dreval A., Marova E.
87. Maternal bereavement after death of a close relative and neural tube defect in the offspring
Ingstrup K.* (DK), Olsen J., Bech B., Nohr E., Li J.
88. Effect of SP6 Acupressure on Cervical Ripening in Nulliparous Women
Jalali Aria K.* (IR), Tork Zahrani S., Ghobadi K., Heshmat R., Shakeri N.
89. Why HPV associated with Head and Neck cancers are increasing? How could we do?
Ziaei T., Jalalilaria K.* (IR), Ziaei F.
90. The incidence of Left sided ovarian endometrioma
Ji Y.* (KR)
91. Prevalence of Co-infections with human papillomavirus and mycoplasma/ureaplasma species in women with abnormal cervical cytology
Ji Y.* (KR)
92. Sucrose doesn't need to be added in vitrification solution for freezing the artificial shrunken mouse blastocysts
Lee K., Joo J.* (KR), Ko K.
93. Comparison of GnRH agonist and antagonist protocols in normoresponder patients who had IVF-ICSI
Kara M.* (TR), Aydin T., Aran T.
94. The effect of counseling in small groups on pregnant women's attitudes about the way of giving birth: An interventional study
Khatiban M.* (IR)
95. Clinical characteristics of pediatric and adolescent women visiting the obstetrics and gynecology department
Kim T.* (KR)
96. Clinical efficacy and complications of Implanon implant
Kim H.* (KR), Seong S., Kim J.
97. The Influence of Body Mass Index on Total Dose of Gonadotropin Used and Other IVF Outcomes in GnRH Antagonist Cycles
Kim H.* (KR), Lee J., Jee B., Ku S., Suh C., Kim S., Choi Y., Kim J., Moon S.
98. Comparison of IVF outcomes according to LH-activity between GnRH antagonist and GnRH agonist ultra-short flare-up protocols in women 40 years of age and older
Kim Y.* (KR), Yuk J., Lee E., Shin J., Ku S., Lee W., Hur J., Lee S.
99. The utility of endometrial and uterine vascularity measurement by transvaginal ultrasonography in predicting pregnancy outcome during frozen-thawed embryo transfer cycles
Joo J. (KR), Kim S.* (KR), Son J.
100. The Predictional Efficacy of Maternal Serum CA125 in Early Pregnancy with Vaginal Bleeding
Moon C., Kim H.* (KR), Kang H., Lee M.
101. Post Partum IUD as an effective method for family planning in Albania.
Koroveshi E.* (AL), Kosova H., Qirko R., Lu R.
102. Hysteroscopic treatment for adenomyosis
Qirko R., Koroveshi E.* (AL), Kosova H., Hoxhaj O., Shahinaj R.
103. Evaluation of Hepatitis B infection in pregnancy and fetal outcome
Goga M., Qirko R., Koroveshi E.* (AL), Nonaj B., Oga A.
104. Spontaneous puberty in a hypopituitary boy after complete craniopharyngioma resection
Kotsa K.* (GR), Melisourgidis K., Yavropoulou M., Yovos I.

105. Laparoscopic excision of ovarian endometriomas in infertile patients and Serum antimullerian hormone levels modifications
Vera Kovacevic, Svetlana Spremovic Radjenovic, Luka M.Andjelic, Gordana Radonjic Lazovic
Kovacevic V.* (RS)
106. Nonsurgical treatment for vaginal introital laxity with radiofrequency thermal therapy: 12-month outcome data
Krychman M.* (US),Sekiguchi, MD, PhD Y.,Utsugisawa MD Y.,Azekosi, MD Y.,Kinjo MD M.,Song MD M.,Kubota MD Y.,Kingsberg PhD S.
107. Preterm deliveries in IVF women with ovulatory dysfunction occur near term
Kuivasaari-Pirinen P.* (FI),Raatikainen K.,Hippeläinen M.,Heinonen S.
108. The role of Autoimmune Thyroiditis in the pathogenesis of infertility in women
Kvashenko V.* (UA),Vustenko V.,Chayka V.
109. Optimization of infertility treatment in women with Autoimmune Thyroiditis
Kvashenko V.* (UA),Vustenko V.
110. Severe sacral nerve damage complicating epidural anesthesia for Caesarean section
Kwon S.* (KR),park J.,cho C.,shin S.
111. Malignant Transformation of Thyroid Tissue in Ovarian Dermoid Cyst
Kwon S.* (KR),park J.,cho C.,cha S.
112. Obstetric management of the conduct of pregnant women with uterine myoma
Lapotka M.* (BY)
113. Pathogenetic mechanisms of uterine fibroids
Lapotka M.* (BY)
114. Double atresic uterus associated with agenesis of cervix and third upper of vagina
Leanza V.* (IT), Leanza G., Palumbo M., Marilli I., Leanza V.
115. Fertility after multiple myomectomy
Leanza V.* (IT),Stracquadanio M.,Ciotta L.,Marchese E.,Leanza G.
116. A retrospective study of bone mineral density in patients with endometrial cancer without bone metastases
Lee J.* (KR),Lee C.
117. Laparoscopic assisted adenomyomectomy using double flap method
Lee K.* (KR),Hwang I.
118. Operative delivery: proposal for a tool helpful in pre-early-labour woman's counseling
Cipriani I.,Calcagno A.,Londero A.* (IT),Visentin S.,Fruscalzo A.,Bertozzi S.,Driul L.,Marchesoni D.
119. Surfactant protein a and d alter lps mediated pro-inflammatory effects on decidual macrophages and could be relevant in parturition
Madhukaran S.* (SG),Gupta T.,Kishore U.
120. Efficacy and safety of micronized progesterone as luteal phase support in ivf cycles
Mamani A.* (MX),Godoy H.,Ponce P.,Alvarado H.,Cedillo L.,Olivares G.,Moreno M.
121. Assessment sperm parameters in infertile couples
Mamani A.* (Mx),Godoy H.,Barberena P.,Lozano J.,Gonzalez L.,Alvarado J.,Cedillo L.,Mera R.
122. The Desire for Multiple Pregnancy among Subfertile Women and Their Partners – “What factors affecting their choice?”
Md Latar I.* (MY),Razali N.
123. Association of Thrombophilia with Adverse Pregnancy Outcomes
Miljanovic O.* (ME),Magic Z.,Teofilov S.,Bulatovic M.,Likic D.,Vojvodic D.,Dakic T.
124. Office-based diagnostic hysteroscopy after recurrent failures of assisted reproductive technologies: Results and effects on the later pregnancy rates.
Montero Pastor N.* (ES),López Carrasco I.,Rodríguez Tabares V.,Moratalla Bartolomé E.,Sanz Espinosa E.,Cano Vieco M.,Bruna Catalán I.
125. Engaging prospective patients through digital marketing
Montgomery V.* (GB)
126. Trophoblast Apoptosis and BRCA1 Expression in Fetal Growth Restriction Pregnancy
Moon C.* (KR),Kim H.,Kang H.,Lee M.

127. Maternal psychological state during the transition to motherhood: A longitudinal study
Mortazavi F.* (IR), Mousavi A., Chaman R.
128. Endocrine disruptors and breast cancer risk – time to consider the environment
Mostafa R.* (AE), Abdel Rahman W., Moustafa Y., Ahmed B.
129. Intervertebral disc height in premenopausal women, treated and untreated postmenopausal women and postmenopausal women with osteoporotic vertebral fractures
Muscat Baron Y.* (MT)
130. Impact of Hormone Replacement Therapy on the Structural-Functional State of Vascular Wall in Postmenopausal Women
Mychka V.* (RU), Tolstov S., Salov I., Kirillova M.
131. Cardiovascular and Metabolic Effects of Hormone Therapy in Perimenopausal Women
Mychka V.* (RU), Kirillova M., Kuznetsova I., Voichenko N.
132. Expression of CD44 in endometrial cells and correlation with adherence to peritoneal mesothelial cells from women with and without endometriosis
Na Y.* (KR)
133. Adenomatoid tumor of the uterus in a patient with transcervical mass
Na Y.* (KR)
134. OHVIRA Syndrome and endometriosis
Nejkovic L.* (RS), Brankovic S.
135. Pregnancy after hysteroscopic resection of APAM – fertility preservation
Nejkovic L.* (RS), Brankovic S.
137. On the question of the feasibility of endometrial samples scanning electron microscopy before controlled ovarian stimulation in women with unsuccessful attempts art history
Nosenko O.* (UA), Sayenko A., Parnitskaya O., Chaika V., Chaika A.
138. Proliferation and apoptosis in the endometrium of infertile women with endometrial complex nonatypical hyperplasia during “implantation window”
Nosenko O.* (UA), Doroshenko V., Postolyuk I., Chaika V.
139. Contemporary therapeutic options of uterine fibroids in women of reproductive age
Novikova V.* (RU)
140. NSAD Stress Questionnaire at Women with Reproductive Disorders
Nyagolova P.*, Mitkov M.
141. Relevance of pelvic-viscera position using MRI and pelvic floor muscle contraction using PFM trainer in female
Okayama H.* (JP), Ninomiya S., Masaki K., Nakanishi K., Mori M., Saito Y., Tsuchikawa S., Endo Y., Morikawa S.
142. The effects of health-promoting life style and anxiety level on ivf outcomes
Onat G.* (TR), Aba Y., Karanisoğlu H., Yazıcı S.
143. Clinical Management of Borderline Ovarian Tumours & Fertility
Ozan H.* (TR), Solak Korkmazer N., Ozmen T.
144. Protective effect of vardenafil on ischemia-reperfusion injury in rat ovary
Hatice B., Ozlem K.* (TR), Mustafa K., Dilek P. (TR)
145. Consultation needs about menopause among women; Qualitative study
Pakseresht S.* (IR)
146. Socio-Demographic of Voluntary Women in Physiological Birth Classes
Pakseresht S.* (IR)
147. Serum Anti-Müllerian hormone levels as a predictive marker in women with amenorrhea
PARK J.* (KR), BAE J., KWON S., KIM J., RHEE J.
148. Role of intraovarian angiotensin-(1-7) on the pathogenesis of polycystic ovaries
Pereira V.* (BR), Reis F., Santos R., Reis A.
149. Acute treatment with royal jelly has an inhibitory effect on the rat uterine tissue
Pereira V.* (BR), Braz L., Viana S., Fakhouri R.
150. Spine fractures after hormone replacement therapy: 20 years of follow-up
Perelló Serra M.* (ES), Peguero A., Ros C., Martínez Serrano M., Castelo-Branco C.

151. Assessment of continuation rates and satisfaction in women using estradiol valerate/dienogest (E2V/DNG) in a dynamic dosing regimen or progestin-only pills (POPs) in a non-interventional study – CONTENT
Perino A., Briggs P., Breilmann J., Serrani M.* (GB), Pattanayak C.
152. Effects of metformin in patients affected by PCOS AND Hyperinsulinism: our experience
Picarelli S.* (IT), De Placido G., Tores A., Strina I., Alviggi C.
153. Chromosomal abnormalities and reproductive failure: a 4 years retrospective study
Pirino A.* (IT), Ulgheri L., Sanna R., Campus P., Soro G., Sotgiu A., Bandiera P., Montella A.
154. The role of the nitric oxide pathway during childbirth of restricted hypoxic fetuses and its potential effect in perinatal period
Pisaneschi S.* (IT)
155. Analysis of diagnostic and therapeutic errors in the conduct of adolescents with oligomenorrhea and secondary amenorrhea
Pyrohova V.* (UA), Tsjolko O.
156. Vagine biotope in women with habitual abortion
Pyrohova V.* (UA), Schuruk N.
157. D- Chiro-Inositol (DCI) modulates insulin and LH secretion in obese PCOS patients
Rattighieri E.* (IT)
158. Breast Cancer Risk comparing Ethinylestradiol vs. Estradiol: Effect on proliferation and apoptosis in human breast cancer cells.
Ruan X.* (CN), Seeger H., Merki-Feld G., Mueck A.
159. Expression of leptin and its receptors in normal human ovaries and in those affected by endometrioma
Rudge C.* (BR), de Oliveira M., Ramos C., Gonçalves H., Sampaio F.
160. The expressions of apoptosis markers are altered in CD4+CD25+FoxP3+ T regulatory lymphocytes in pre-eclampsia.
Darmochwal-Kolarz D., Saito S.* (PL), Kolarz B., Rolinski J., Leszczynska-Gorzela B., Oleszczuk J.
161. Pregnancy outcome after illegal induced abortion in Iran
Samani E.* (IR)
162. Sperm vitrification: Non-permeable cryoprotectants – necessary or not?
Krebs T., Wedler A., Maas D., Saymé N.* (DE)
163. Delayed delivery after intrauterine infection in twin pregnancy at 19 and at 25 weeks
Scaramuzzi F.* (IT), Laforgia N., Cipriani A., Messina R., varsalone F., Ioverro G.
164. Laparoscopic cystectomy of bilateral endometriomas negatively affects ovarian reserve
Solomatina A., Shabrina O.*, Kavteladze E., Zarubina M., Dzidzariya F.
165. Is Oocyte Pick Up (OPU) in In Vitro Fertilization (IVF) preventing Controlled Ovarian Hyperstimulated (COH) ovaries from cancer? PDGF-dependent chemotaxis of fallopian tube carcinoma-associated stromal cells to ovulating follicle underlies the ectopic origin of ovarian carcinoma
Shih Chen C.* (TW)
166. Evaluation of extra-corporeal shock wave therapy for the patients of peyronie's disease a preliminary report
Shimpi R.* (IN)
167. Changes in haemodynamics in testicular artery after varicocelelectomy - a long term follow-up
Shimpi R.* (IN)
168. Sacro-pubic teratoma in an intrauterine fetus, coexisting with an extra-uterine rapture - Case Report
Salvanos G., Mavrogianis D., Konstadatou K., Augoulea A., Skolarikos P.* (GR)
169. Fertility rate after hysteroscopic excision of benign endometrial lesions
Drakondaidis A., Charatsi D., Bourda P., Skolarikos P.* (GR)
170. Immunoistochemical detection of ki-67 in the endometrium of pinealectomized rats treated with melatonin during the proestrus phase
Soares-Jr J.* (BR), Maganhin C., Sasso G., da Silva R., Fuchs L., Baracat M., Simões R., Rossi A., Simões M., Baracat E.

171. Immunoexpression of cyp17 in the ovary of pinealectomized and melatonin treated rats
Soares-Jr J.* (BR), Sasso G., da Silva R., Fuchs L., Baracat M., Simões R., Rossi A., Carbonel A., Simões M., Baracat E.
172. Restoration of reproduction after UAE
Stakeeva C.* (KG)
173. Chronobiological rhythms of melatonin secretion in climacteric women with sleep disorders
Suturina L.* (RU), Madaeva I., Kolesnikova L., Semenova N., Solodova E., Sholohov L.
174. Students' Premenstrual Symptoms Severity in Dorms of Tehran University of Medical Sciences
Barkhaordari F. (IR), Taavoni S.* (IR), Haghani H.
175. Downregulation of CD26 under hypoxic condition could enhance migration of eutopic endometriotic stromal cells
Tan C.* (SG)
176. Ultrasound aspects in PMA and pre-treatment with Inositol, in Polycystic Ovary: Results and data.
Tossichetti L.* (IT), Rossi A., Claretti C.
177. Prolactin And Fertility: Treatment in Assisted Reproduction, with D-chiro-inositol, bromocriptine and cramberry. Ultrasound aspects, Results and Data.
Tossichetti L.* (IT), Rossi A., Claretti C.
178. A genome-wide expression profile of decidual tissue in preeclampsia
Trifonova E.* (RU), Ershov N., Gabdulina T., Stepanov V.
179. Orgasmic changes after gynecological and breast cancer treatment in woman
Vaidakis D.* (GR), Tatsi C., Pilatec L., Kouloura A., Makris G.
180. Changes in female sexuality after breast cancer treatment in fertile woman
Vaidakis D.* (GR), Kouloura A., Tatsi C., Pilatec L., Poulakaki N.
181. The contraceptive methods habits among women aged 16 - 49 in I. Vasaraudze's Private Clinic Ltd.
Vasaraudze I.* (LV), Rezeberga D., Lejnieks A., Erts R.
182. The habits of using contraceptive methods among fertile age women in I. Vasaraudze's Private Clinic Ltd., Latvia
Vasaraudze I.* (LV), Rezeberga D., Lejnieks A.
183. Serum hemoglobin and ferritin level among fertile age LNG IUS users in I. Vasaraudze's Private Clinic Ltd., Latvia
Vasaraudze I.* (LV), Rezeberga D., Lejnieks A., Erts R.
184. Bleeding cervical fibroid necessitating internal iliac artery ligation – a case report
Vella K.* (MT), Camillieri Agius R., Muscat Baron Y., Cassar K., Scerri A.
185. The Significance of Serum Progesterone level in the Luteal phase in assisted reproduction cycles
Tsar O., Vella K.* (MT), Vasallo M., Brincat M.
186. A rare case of single cord insertion with two branches in uniovular twins
Tsar O., Vella K.* (MT), Chetcuti D., Vassallo M., Cutajar K., Micallef Fava A., Brincat M., Aquilina J.
187. Metabolic changes with contraceptives, comparison with two different progestins
Vilariño, A; Lioy, G; Fernandez, M, Urthiague, M; Mural J, Lange D ; Provenzano, S; Dotto, J; Contreras Ortiz, O
188. Decreased fertility in survivors of childhood cancer: differential effect of chemotherapy and radiotherapy on ovarian endocrine function and ovarian reserve.
Villa P, Lazzareschi I, Sanso' C, Rossodivita A, Moruzzi MC, Vacca L, Riccardi R, Scambia G.
189. An Italian experience in ENG implant users.
Visconti F.* (IT), Zullo F., Cibarelli F., Marra M., Miele G., D'Alessandro P., Guida M.
190. Proposal for a flow-chart: contraceptive counseling and management of bleeding with ENG implant.
Visconti F.* (IT), Zullo F., Cibarelli F., Marra M., Buonomo B., D'Alessandro P., Guida M.
191. A clinical observation of natural pregnancy in woman with resistant prolactinoma after complex therapy of selective and non-selective dopamine agonists.
Vorotnikova S.* (RU), Fedorova N., Pigarova E., Dzeranova L., Rozhinskaya L.

192. The effect of Udenafil(Zydena) on the fertilization and early embryo development in mice
Yang H.* (KR)
193. Ovarian vascular flow indices by three-dimensional ultrasound Doppler is associated with the endocrine markers of ovarian reserve
Yi K.* (KR),Shin J.,Jeon H.,Park H.,Kim T.,Hur J.,Kim S.
194. Mistletoe therapy in deeply infiltrating endometriosis.
YongTaik L.* (KR),JunYoung H.
195. Summary of the study of “Qlaira” medication
Yutskovskaya Y.* (RU),Dvorianinova I.
-
- The Determination of the Behaviours About Family Planning of the Adolescents
Aba Y. (TR),Onat Bayram G.,Durmaz A.
 - Prevalence and Severity of Menopausal Symptoms and Related Factors Among Women 40-60 Years in Kashan, Iran
Abedzadeh Kalahrudi M. (IR),Taebi M.,saber F.,Sadat Z.
 - Prevalence of human papillomavirus among women with pap-smears negative for intra-epithelial lesions or malignancy
Al Eyd G. (AE)
 - Detection of PTEN, IGF I and IGF IR immunoreactivity in endometrial hyperplasia and adenocarcinoma.
Asaturova A. (RU)
 - Evaluation of serum creatinephosphokinase in diagnosis of tubal ectopic pregnancy compared with intrauterine pregnancy and threatened abortion
asgharnia M. (IR),Faraji R.,Mirblouk F.,Atrkar Roshan Z.,Parvizi A.
 - Biomarkers for cardiovascular risk assessment in polycystic ovary syndrome
Atanasova Boshku A. (MK)
 - Burn out Syndrome and genital psychosomatic symptoms
Bocchi de Souza L. (BR)
 - Association of two types of birth defects in a consanguineous Tunisian couple- spina bifida and valvular pulmonary stenosis- Is there a genetic relation via MTHFR, NOS3 genes or 22q11 region
Bouayed N. (TN),Abdelhedi R.,Salleme A.,Rebai T.
 - The frequency of Celiac Disease among women with reproductive disorders.
Bykova S. (RU),Tetruashvily N.,Parfenov A.,Petuhova G.,Repina E.
 - Reproductive disorders with Celiac Disease women. Etiotropic treatment influence.
Bykova S. (RU),Parfenov A.,Sabelnikova E.,Krumbs L.,Gudkova R.,Vorobleva N.
 - The level of prolactin and folic acid with CD patients.
Bykova S. (RU),Drozdov V.,Varvanina G.,Parfenov A.
 - Breast Cancer and Fertility Preservation. A Case Report and Literature Review
Gonzalez-Jara L. (MX),Godoy-Morales H.,Alfeiran-Ruiz A.,Jacobo-Najera S.,Lozano-Sanchez J.,Cedillo-Garcia Lascurain L. (MX),Alvarado-Delgado H.
 - Reference ranges for coagulation parameters during the third trimester of pregnancy and the optimal cut-off values for pregnancy induced hypertension
Chen Y. (CN)
 - Changes in endometrial secretions due to emergency contraception modulate sperm function
Chirinos Espin M. (MX),Durand M.,Gonzalez-Gonzalez M.,Cano F.,Koistinen R.,Seppala M.,Larrea F.
 - Analysis of selected indications and evaluation of genetic amniocentesis results aimed to detect trisomy 21 and obtained in the latter decade
Chuchracki M. (PL),Sędziak A.,Ziółkowska K.,Sklepik K.,Opala T.
 - Robotically approach for endometriotic bladder lesion
Colosi E. (IT),Tamburro S.
 - Effect of Massage Therapy on Menopausal Symptoms: a Randomized Clinical Trial Study
Darsareh F. (IR),Taavoni S.,Jolae S.,Haghani H.

- Relationship between body mass index and nature of adnexal masses
Terzic M.,Dotlic J. (RS),Likic I.,Kocijancic D.,Milenkovic S.,Brndusic N.,Maricic S.,Pilic I.,Bila J.
- Determine overall mental and sexual problems in postmenopausal women referred to health centers Shush city
Ebrahimian F. (IR),Afshari P.,Daneshi A.
- Study of population for weight increase, Androidic obesity, Gynoidic obesity and factors connected with it in menopause and non- menopause women.
Ebrahimian F. (IR),Zargar M.
- Implications of obesity in pregnancies complicated with gestational diabetes
Ebrahimian F. (IR)
- Tumor necrosis factor- α , interleukin-8 and monocyte chemotactic protein-1 changes during pregnancy and their correlation with maternal obesity
Elksne K. (LV)
- Pre-pregnancy body mass index and excessive weight gain during pregnancy as a risk factors for negative obstetrical outcome
Elksne K. (LV),Paunina Z.,Jurka A.,Rezeberga D.,Tretjakovs P.
- Polymorphisms and Ovarian Response In Patients Undergoing ICSI Program
El Sirkasi M.* (LY)
- Luteal estradiol administration for poor-responders improves mature oocyte number.
Farimani M. (IR)
- The "Ice Boy". Devitrified embryo transfer, derived from devitrified oocytes and thawed sperm. A case report.
Jacobo S. (MX),Godoy H.,González L.,Moreno M.,Ulloa A.,García Lascurain L.,Lozano J.,Alvarado H.
- The social and cultural aspects of puberty in Iranian adolescent girls: A qualitative content analysis
Hamzehgardeshi Z. (IR)
- Modern look at pregnancy management for pregnant with intrauterine fetal death in history
Ignatko I. (RU),Strizhakov A.,Popova Y.
- Fertility preservation in cervical cancer
Karimi Zarchi M. (IR)
- Evaluation the effect of GnRh agonist on menstrual reverse on breast cancer cases on treatment of cyclophosphamide regimen
Karimi Zarchi M. (IR)
- The role of HPV in cervical cancer and HPV vaccine in screening of cervical cancer in developing countries
Karimi Zarchi M. (IR)
- The malignant risk of endometrial polyps in premenopausal women
Seong S.,Kim J. (KR), Kim H.
- Current status of female sexual dysfunction in Korea
Kim T. (KR),Lee B.
- The correlation among BMI, oocyte maturity and IVF outcome in Korean women aged under 38 years
Kim W. (KR),Kim H.,Lee J.,Jee B.,Ku S.,Suh C.,Kim S.,Choi Y.,Kim J.,Moon S.
- Role of hysteroscopy in women selected for IVF
Konstadatou K. (GR),Pavlakis M.,Mavrogiannis D.,Skolarikos P.
- Clinical Study of IVF and ZIFT
Kosarian M. (IR),Ghavamiadel H.
- Okadaic acid-sensitive phosphatase is related to MII/G1 transition in mouse oocytes
Kuwahara A. (JP),Moride N.,Kuwahara M.,Tanaka Y.,Irahara M.
- Uterine rupture risk in pregnancy after myomectomy.
Kuzmina T. (RU)
- Genetic polymorphism of PRKCDPB is associated with an increased risk of endometrial cancer
Lee J. (KR),Ki K.
- Clinical significance of FOXP3-positive regulatory T cells in cervical cancer
Lee J. (KR),Ki K.

- A new solution for the prevention of intrauterine adhesion after hysteroscopic / resectoscopic surgery: PROTADE®
Lee S. (KR), Shin J., Jeong K., Kim Y., Yoo E., Chung H., Kim T., Kang B.
- Cystitis glandularis with cystitis cystica presenting recurrent gross hematuria with tumorous lesion in the urinary bladder: A rare appearance of disease.
Lee S. (KR), Jeong K., Moon H., Chung H.
- The phospholipids of ovarian's membrane and peritoneal fluid in the spread of pelvic endometriosis.
Makhmudova G. (RU)
- Comparison of post partum depression among mothers conceived by ART and mothers conceived naturally
Malekzadeh F. (IR), Alizadegan S., Amirchaghmaghi E., Khalili G., Ezabadi Z., Daliri L.
- How can we increase the level of satisfaction of ours patients in assisted reproductive consultation?
Martín Cabrejas B. (ES), Sanz García V., Lorenzo Martínez S., García Rubio M., Martín Caballero C., Albi González M.
- The advantages of mini-laparoscopic surgery compared to conventional laparoscopic surgery for early stage endometriosis
Oh S. (KR), Kim T.
- Breech delivery: vaginal delivery of cesrean section
Petronijevic M. (RS), Vrzic Petronijevic S., Bratic D.
- New decision-tree model for defining the risk of Recurrent Reproductive Failure.
Ramos-Medina R. (ES), Garcia-Segovia A., Leon J., Alonso B., Tejera-Alhambra M., Gil J., Caputo J., Seyfferth A., Aguaron de la Cruz A., Vicente A., Ordoñez D., Alonso J., Carrillo de Albornoz E., Carbone J., Caballero P., Fernandez-Cruz E., Ortiz-Quintana L., Sanchez-Ramon S.
- Comparison between sperm DNA fragmentation and OxyDNA in samples with severe oligoasthenozoospermia.
Scarselli F. (IT), Lobascio A., Casciani V., Colasante A., Zavaglia D., Minasi M., Greco E.
- Tobacco smoking and passive exposure to smoke: declarations vs serum concentration of cotinine in women of procreative age
Sedziak A. (PL), Florek E., Chuchracki M., Kulza M., Ziółkowska K.
- Magnesium sulfate potentiates DigiFab reversal of preeclampsia-induced Na/K-ATPase inhibition
Solodovnikova N. (RU)
- Polymorphisms of estrogen receptor- α gene in Brazilian women with high breast density after menopause
Souza M. (Br), Fonseca A., Barros N., Mendonça E., Carvalho K., Soares J., Baracat E.
- Low rates of nickel allergy and high rates of asthma in women with endometriosis: Korean National Registry Data
Yuk J. (KR), Kim Y., Yi K., Hur J., Shin J.

COVER
Venezia, S.Marco (iStockphoto)

EDITING

Biomedical Technologies

GRAPHIC DESIGN

Stefano Berti - Biomedical Technologies

PRINTER

Istituto Arti Grafiche Mengarelli
www.iagmengarelli.it



International Menopause Society

promoting education and research on all aspects of adult women's health

14 WORLD CONGRESS MENOPAUSE

ADVANCING GLOBAL HEALTH FOR WOMEN AT MIDLIFE



**CAN
CUN
2014**


May 1–4, 2014 Cancun, Mexico
Cancun Center Conventions & Exhibitions



www.imscancun2014.com

Fostimon[®]

Highly purified hFSH



Evidence of life